Predictors	O
of	O
Individual	O
Response	O
to	O
Placebo	O
or	O
Tadalafil	O
5mg	O
among	O
Men	O
with	O
Lower	O
Urinary	O
Tract	O
Symptoms	O
Secondary	O
to	O
Benign	B-DS
Prostatic	I-DS
Hyperplasia	I-DS
:	O
An	O
Integrated	O
Clinical	O
Data	O
Mining	O
Analysis	O

Competing	O
Interests	O
:	O
I	O
have	O
read	O
the	O
journal	O
'	O
s	O
policy	O
and	O
the	O
authors	O
of	O
this	O
manuscript	O
have	O
the	O
following	O
competing	O
interests	O
:	O
Gianluca	O
D	O
’	O
Anzeo	O
,	O
Carsten	O
Henneges	O
and	O
Andrea	O
Rossi	O
are	O
full	O
-	O
time	O
employees	O
of	O
Eli	O
Lilly	O
and	O
Company	O
.	O

Hartwig	O
Büttner	O
is	O
a	O
full	O
-	O
time	O
employee	O
and	O
minor	O
stockholder	O
of	O
Eli	O
Lilly	O
and	O
Company	O
.	O

F	O
.	O

Fusco	O
and	O
J	O
.	O

Curtis	O
Nickel	O
are	O
both	O
consultants	O
and	O
speakers	O
for	O
Eli	O
Lilly	O
and	O
Company	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
FF	O
GD	O
CH	O
AR	O
JCN	O
.	O

Performed	O
the	O
experiments	O
:	O
CH	O
.	O

Analyzed	O
the	O
data	O
:	O
FF	O
HB	O
JCN	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
CH	O
.	O

Wrote	O
the	O
paper	O
:	O
FF	O
GD	O
CH	O
AR	O
JCN	O
.	O

Critical	O
revision	O
of	O
the	O
manuscript	O
for	O
important	O
intellectual	O
content	O
:	O
FF	O
GD	O
CH	O
AR	O
HB	O
JCN	O
.	O

Statistical	O
analysis	O
:	O
CH	O
.	O

Obtained	O
funding	O
:	O
GD	O
AR	O
.	O

Administrative	O
,	O
technical	O
or	O
material	O
support	O
:	O
CH	O
HB	O
.	O

Supervision	O
:	O
FF	O
GD	O
CH	O
AR	O
HB	O
JCN	O
.	O

Background	O

A	O
significant	O
percentage	O
of	O
patients	O
with	O
lower	O
urinary	O
tract	O
symptoms	O
(	O
LUTS	O
)	O
secondary	O
to	O
benign	B-DS
prostatic	I-DS
hyperplasia	I-DS
(	O
BPH	B-DS
)	O
achieve	O
clinically	O
meaningful	O
improvement	O
when	O
receiving	O
placebo	O
or	O
tadalafil	O
5mg	O
once	O
daily	O
.	O

However	O
,	O
individual	O
patient	O
characteristics	O
associated	O
with	O
treatment	O
response	O
are	O
unknown	O
.	O

Methods	O

This	O
integrated	O
clinical	O
data	O
mining	O
analysis	O
was	O
designed	O
to	O
identify	O
factors	O
associated	O
with	O
a	O
clinically	O
meaningful	O
response	O
to	O
placebo	O
or	O
tadalafil	O
5mg	O
once	O
daily	O
in	O
an	O
individual	O
patient	O
with	O
LUTS	O
-	O
BPH	B-DS
.	O

Analyses	O
were	O
performed	O
on	O
pooled	O
data	O
from	O
four	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
clinical	O
studies	O
,	O
including	O
about	O
1	O
,	O
500	O
patients	O
,	O
from	O
which	O
107	O
baseline	O
characteristics	O
were	O
selected	O
and	O
8	O
response	O
criteria	O
.	O

The	O
split	O
set	O
evaluation	O
method	O
(	O
1	O
,	O
000	O
repeats	O
)	O
was	O
used	O
to	O
estimate	O
prediction	O
accuracy	O
,	O
with	O
the	O
database	O
randomly	O
split	O
into	O
training	O
and	O
test	O
subsets	O
.	O

Logistic	O
Regression	O
(	O
LR	O
),	O
Decision	O
Tree	O
(	O
DT	O
),	O
Support	O
Vector	O
Machine	O
(	O
SVM	O
)	O
and	O
Random	O
Forest	O
(	O
RF	O
)	O
models	O
were	O
then	O
generated	O
on	O
the	O
training	O
subset	O
and	O
used	O
to	O
predict	O
response	O
in	O
the	O
test	O
subset	O
.	O

Prediction	O
models	O
were	O
generated	O
for	O
placebo	O
and	O
tadalafil	O
5mg	O
once	O
daily	O
Receiver	O
Operating	O
Curve	O
(	O
ROC	O
)	O
analysis	O
was	O
used	O
to	O
select	O
optimal	O
prediction	O
models	O
lying	O
on	O
the	O
ROC	O
surface	O
.	O

Findings	O

International	O
Prostate	O
Symptom	O
Score	O
(	O
IPSS	O
)	O
baseline	O
group	O
(	O
mild	O
/	O
moderate	O
vs	O
.	O
severe	O
)	O
for	O
active	O
treatment	O
and	O
placebo	O
achieved	O
the	O
highest	O
combined	O
sensitivity	O
and	O
specificity	O
of	O
70	O
%	O
and	O
~	O
50	O
%	O
for	O
all	O
analyses	O
,	O
respectively	O
.	O

This	O
was	O
below	O
the	O
sensitivity	O
and	O
specificity	O
threshold	O
of	O
80	O
%	O
that	O
would	O
enable	O
reliable	O
allocation	O
of	O
an	O
individual	O
patient	O
to	O
either	O
the	O
responder	O
or	O
non	O
-	O
responder	O
group	O

Conclusions	O

This	O
extensive	O
clinical	O
data	O
mining	O
study	O
in	O
LUTS	O
-	O
BPH	B-DS
did	O
not	O
identify	O
baseline	O
clinical	O
or	O
demographic	O
characteristics	O
that	O
were	O
sufficiently	O
predictive	O
of	O
an	O
individual	O
patient	O
response	O
to	O
placebo	O
or	O
once	O
daily	O
tadalafil	O
5mg	O
.	O

However	O
,	O
the	O
study	O
reaffirms	O
the	O
efficacy	O
of	O
tadalalfil	O
5mg	O
once	O
daily	O
in	O
the	O
treatment	O
of	O
LUTS	O
-	O
BPH	B-DS
in	O
the	O
majority	O
of	O
patients	O
and	O
the	O
importance	O
of	O
evaluating	O
individual	O
patient	O
need	O
in	O
selecting	O
the	O
most	O
appropriate	O
treatment	O
.	O

Introduction	O

Lower	O
urinary	O
tract	O
symptoms	O
(	O
LUTS	O
)	O
secondary	O
to	O
benign	B-DS
prostatic	I-DS
hyperplasia	I-DS
(	O
BPH	B-DS
)	O
are	O
a	O
common	O
problem	O
,	O
affecting	O
more	O
than	O
50	O
%	O
of	O
men	O
aged	O
50	O
years	O
and	O
older	O
[	O
1	O
].	O

Medical	O
treatment	O
has	O
focused	O
mainly	O
on	O
the	O
use	O
of	O
α	O
-	O
blocking	O
agents	O
and	O
5	B-GP
-	I-GP
α	I-GP
reductase	I-GP
inhibitors	O
,	O
either	O
alone	O
or	O
in	O
combination	O
,	O
and	O
aims	O
to	O
alleviate	O
symptoms	O
as	O
well	O
as	O
alter	O
the	O
course	O
of	O
disease	O
progression	O
and	O
prevent	O
complications	O
[	O
2	O
].	O

Treatment	O
options	O
for	O
LUTS	O
-	O
BPH	B-DS
have	O
since	O
increased	O
with	O
regulatory	O
approval	O
of	O
tadalafil	O
5mg	O
once	O
daily	O
,	O
a	O
long	O
-	O
acting	O
phosphodiesterase	B-GP
type	I-GP
5	I-GP
(	O
PDE	B-GP
-	I-GP
5	I-GP
)	O
inhibitor	O
,	O
initially	O
in	O
the	O
US	O
in	O
2011	O
and	O
subsequently	O
in	O
the	O
EU	O
and	O
other	O
major	O
territories	O
in	O
2012	O
[	O
3	O
].	O

Treatment	O
of	O
LUTS	O
-	O
BPH	B-DS
,	O
either	O
alone	O
or	O
with	O
coexisting	O
erectile	B-DS
dysfunction	I-DS
(	O
ED	B-DS
),	O
with	O
PDE	B-GP
-	I-GP
5	I-GP
inhibitors	O
and	O
notably	O
tadalafil	O
5mg	O
,	O
has	O
recently	O
been	O
added	O
to	O
EU	O
-	O
wide	O
treatment	O
guidelines	O
for	O
non	O
-	O
neurogenic	O
LUTS	O
[	O
4	O
].	O

The	O
efficacy	O
of	O
once	O
daily	O
tadalafil	O
5mg	O
in	O
LUTS	O
-	O
BPH	B-DS
has	O
been	O
demonstrated	O
in	O
four	O
randomized	O
controlled	O
trials	O
(	O
RCTs	O
)	O
[	O
5	O
;	O
6	O
;	O
7	O
;	O
8	O
].	O

At	O
a	O
lower	O
dose	O
of	O
2	O
.	O
5mg	O
per	O
day	O
,	O
tadalafil	O
did	O
not	O
consistently	O
alleviate	O
symptoms	O
of	O
LUTS	O
-	O
BPH	B-DS
while	O
higher	O
doses	O
of	O
10	O
and	O
20mg	O
per	O
day	O
provided	O
only	O
minimal	O
additional	O
improvement	O
over	O
the	O
5mg	O
once	O
daily	O
dose	O
[	O
5	O
].	O

Assessment	O
of	O
treatment	O
response	O
(	O
primary	O
endpoint	O
)	O
was	O
based	O
primarily	O
on	O
the	O
International	O
Prostate	O
Symptom	O
Score	O
(	O
IPSS	O
),	O
a	O
validated	O
,	O
self	O
-	O
administered	O
,	O
1	O
-	O
month	O
recall	O
questionnaire	O
that	O
has	O
good	O
reliability	O
for	O
recall	O
of	O
obstructive	O
and	O
urinary	O
problems	O
and	O
their	O
global	O
impact	O
on	O
quality	O
of	O
life	O
(	O
QoL	O
).	O

The	O
IPSS	O
is	O
the	O
most	O
widely	O
used	O
instrument	O
to	O
assess	O
the	O
severity	O
of	O
BPH	B-DS
-	O
related	O
LUTS	O
-	O
symptoms	O
and	O
gauge	O
response	O
to	O
treatment	O
[	O
9	O
;	O
10	O
].	O

An	O
integrated	O
analysis	O
of	O
the	O
four	O
RCTs	O
confirmed	O
that	O
tadalafil	O
5mg	O
achieved	O
significantly	O
greater	O
improvements	O
in	O
total	O
IPSS	O
score	O
,	O
IPSS	O
voiding	O
subscore	O
,	O
IPSS	O
storage	O
subscore	O
and	O
IPSS	O
QoL	O
Index	O
score	O
versus	O
placebo	O
[	O
11	O
].	O

A	O
separate	O
analysis	O
of	O
IPSS	O
storage	O
and	O
voiding	O
subscores	O
,	O
showed	O
both	O
were	O
significantly	O
improved	O
in	O
the	O
active	O
treatment	O
arms	O
compared	O
with	O
placebo	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
that	O
both	O
storage	O
and	O
voiding	O
subscores	O
made	O
a	O
nearly	O
linear	O
contribution	O
to	O
total	O
IPSS	O
in	O
a	O
4	O
:	O
6	O
ratio	O
that	O
was	O
maintained	O
from	O
baseline	O
to	O
endpoint	O
[	O
12	O
].	O

In	O
pooled	O
subgroup	O
analyses	O
,	O
significant	O
improvements	O
in	O
IPSS	O
total	O
score	O
were	O
observed	O
regardless	O
of	O
baseline	O
LUTS	O
severity	O
(	O
IPSS	O
<	O
20	O
/≥	O
20	O
),	O
age	O
(≤	O
65	O
/>	O
65	O
years	O
),	O
recent	O
use	O
of	O
α	O
-	O
blocking	O
agents	O
or	O
PDE	B-GP
-	I-GP
5	I-GP
inhibitors	O
,	O
total	O
testosterone	O
level	O
(<	O
300	O
/≥	O
300ng	O
/	O
dl	O
),	O
or	O
prostate	B-GP
-	I-GP
specific	I-GP
antigen	I-GP
(	O
PSA	B-GP
)	O
predicted	O
prostate	O
volume	O
(≤	O
40	O
/>	O
40ml	O
),	O
while	O
tadalafil	O
was	O
well	O
tolerated	O
across	O
all	O
subgroups	O
[	O
13	O
].	O

A	O
further	O
post	O
-	O
hoc	O
integrated	O
analysis	O
of	O
the	O
data	O
from	O
the	O
four	O
RCTs	O
showed	O
that	O
approximately	O
two	O
-	O
thirds	O
of	O
tadalafil	O
-	O
treated	O
patients	O
achieved	O
a	O
clinically	O
meaningful	O
improvement	O
(	O
CMI	O
)	O
in	O
LUTS	O
-	O
BPH	B-DS
symptoms	O
,	O
as	O
defined	O
by	O
a	O
total	O
IPSS	O
improvement	O
of	O
≥	O
3	O
points	O
or	O
≥	O
25	O
%	O
from	O
randomization	O
to	O
endpoint	O
at	O
Week	O
12	O
[	O
14	O
].	O

Moreover	O
,	O
tadalafil	O
5mg	O
once	O
daily	O
,	O
demonstrated	O
increasing	O
benefit	O
over	O
placebo	O
as	O
the	O
efficacy	O
threshold	O
was	O
raised	O
from	O
≥	O
25	O
%	O
to	O
a	O
demanding	O
≥	O
50	O
%	O
and	O
≥	O
75	O
%	O
improvement	O
in	O
IPSS	O
[	O
14	O
].	O

Being	O
able	O
to	O
identify	O
which	O
individual	O
patient	O
is	O
most	O
likely	O
to	O
respond	O
well	O
to	O
treatment	O
with	O
placebo	O
or	O
tadalafil	O
,	O
rather	O
than	O
just	O
knowing	O
its	O
average	O
benefit	O
to	O
a	O
subgroup	O
of	O
patients	O
,	O
would	O
be	O
clinically	O
useful	O
and	O
consistent	O
with	O
the	O
growing	O
trend	O
towards	O
more	O
patient	O
-	O
tailored	O
treatment	O
[	O
15	O
].	O

Treatment	O
directed	O
at	O
patients	O
most	O
likely	O
to	O
achieve	O
CMI	O
would	O
help	O
address	O
the	O
problem	O
that	O
for	O
too	O
many	O
patients	O
with	O
LUTS	O
-	O
BPH	B-DS
,	O
medical	O
therapy	O
achieves	O
only	O
a	O
fair	O
-	O
to	O
-	O
good	O
improvement	O
in	O
symptoms	O
[	O
16	O
].	O

In	O
this	O
integrated	O
clinical	O
data	O
mining	O
analysis	O
,	O
we	O
set	O
out	O
to	O
identify	O
the	O
factors	O
associated	O
with	O
response	O
to	O
placebo	O
or	O
tadalafil	O
5mg	O
once	O
daily	O
in	O
an	O
individual	O
patient	O
with	O
LUTS	O
-	O
BPH	B-DS
.	O

Implicit	O
in	O
a	O
study	O
of	O
this	O
nature	O
was	O
the	O
need	O
to	O
carefully	O
estimate	O
the	O
true	O
prediction	O
performance	O
of	O
a	O
factor	O
for	O
unknown	O
patients	O
.	O

Methods	O

Study	O
design	O

This	O
clinical	O
data	O
mining	O
analysis	O
was	O
based	O
on	O
the	O
Knowledge	O
Discovery	O
in	O
Databases	O
(	O
KDD	O
)	O
process	O
and	O
was	O
set	O
up	O
to	O
be	O
consistent	O
with	O
the	O
underlying	O
principles	O
of	O
data	O
mining	O
[	O
17	O
].	O

Applied	O
data	O
mining	O
algorithms	O
were	O
considered	O
suitable	O
only	O
if	O
a	O
graphical	O
presentation	O
could	O
be	O
obtained	O
that	O
could	O
be	O
followed	O
by	O
practicing	O
physicians	O
.	O

We	O
therefore	O
focused	O
on	O
models	O
that	O
were	O
easily	O
visualised	O
or	O
those	O
expected	O
to	O
yield	O
good	O
predictive	O
outcomes	O
.	O

Our	O
aim	O
was	O
to	O
produce	O
an	O
output	O
that	O
could	O
be	O
displayed	O
on	O
paper	O
and	O
used	O
by	O
clinicians	O
and	O
so	O
we	O
decided	O
at	O
the	O
outset	O
to	O
adopt	O
the	O
simplest	O
model	O
first	O
.	O

This	O
can	O
be	O
seen	O
by	O
the	O
inclusion	O
of	O
single	O
decision	O
rules	O
(	O
SDRs	O
).	O

These	O
models	O
consider	O
just	O
one	O
clinical	O
variable	O
at	O
a	O
time	O
to	O
predict	O
one	O
response	O
variable	O
,	O
without	O
any	O
additions	O
,	O
and	O
they	O
perform	O
well	O
.	O

Rigorous	O
care	O
was	O
taken	O
to	O
evaluate	O
the	O
prediction	O
error	O
for	O
unknown	O
data	O
.	O

Every	O
effort	O
was	O
made	O
to	O
control	O
for	O
potential	O
data	O
mining	O
biases	O
(	O
i	O
.	O
e	O
.	O
those	O
induced	O
by	O
applying	O
too	O
flexible	O
data	O
mining	O
algorithms	O
or	O
those	O
stemming	O
from	O
the	O
desire	O
to	O
achieve	O
100	O
%	O
accurate	O
predictions	O
).	O

To	O
this	O
end	O
we	O
adhered	O
to	O
a	O
pre	O
-	O
specified	O
statistical	O
analysis	O
plan	O
(	O
SAP	O
),	O
which	O
did	O
not	O
allow	O
for	O
removal	O
of	O
data	O
points	O
.	O

We	O
set	O
out	O
our	O
experience	O
first	O
,	O
wrote	O
down	O
our	O
approach	O
,	O
and	O
kept	O
to	O
it	O
without	O
deviation	O
.	O

We	O
did	O
not	O
intend	O
to	O
optimize	O
prediction	O
performance	O
further	O
than	O
what	O
had	O
been	O
pre	O
-	O
specified	O
.	O

To	O
do	O
so	O
would	O
only	O
bias	O
results	O
for	O
models	O
that	O
are	O
adapted	O
and	O
optimized	O
for	O
a	O
specific	O
combination	O
for	O
the	O
training	O
algorithm	O
and	O
evaluation	O
method	O
,	O
and	O
which	O
are	O
thereby	O
unlikely	O
to	O
capture	O
the	O
clinical	O
information	O
that	O
is	O
predictive	O
in	O
clinical	O
practice	O
.	O

More	O
extensive	O
methodological	O
details	O
not	O
covered	O
here	O
are	O
provided	O
in	O
Supporting	O
Information	O
.	O

Data	O
sources	O
and	O
pre	O
-	O
processing	O

Data	O
for	O
this	O
clinical	O
data	O
mining	O
analysis	O
were	O
pooled	O
from	O
four	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
clinical	O
studies	O
(	O
NCT00384930	O
,	O
NCT00827242	O
,	O
NCT00855582	O
,	O
NCT00970632	O
),	O
all	O
of	O
which	O
had	O
a	O
broadly	O
similar	O
design	O
and	O
enrolled	O
patients	O
with	O
LUTS	O
-	O
BPH	B-DS
(	O
Fig	O
1	O
)	O
[	O
6	O
;	O
7	O
;	O
8	O
;	O
16	O
].	O

Common	O
inclusion	O
criteria	O
for	O
all	O
four	O
studies	O
were	O
age	O
≥	O
45	O
years	O
,	O
LUTS	O
-	O
BPH	B-DS
duration	O
of	O
>	O
6	O
months	O
,	O
total	O
IPSS	O
≥	O
13	O
,	O
and	O
maximum	O
urinary	O
flow	O
rate	O
(	O
Qmax	O
)	O
≥	O
4	O
to	O
≤	O
15ml	O
/	O
s	O
prior	O
to	O
the	O
placebo	O
lead	O
-	O
in	O
period	O
.	O

Patients	O
were	O
excluded	O
if	O
PSA	B-GP
was	O
>	O
10ng	O
/	O
ml	O
(	O
or	O
for	O
PSA	B-GP
4	O
–	O
10ng	O
/	O
ml	O
,	O
prostate	B-DS
malignancy	I-DS
had	O
to	O
be	O
excluded	O
),	O
if	O
post	O
-	O
void	O
residual	O
(	O
PVR	O
)	O
urine	O
volume	O
was	O
≥	O
300ml	O
,	O
or	O
if	O
they	O
had	O
used	O
finasteride	O
or	O
dutasteride	O
within	O
3	O
or	O
6	O
months	O
(	O
12	O
months	O
in	O
one	O
study	O
),	O
respectively	O
.	O

Following	O
screening	O
and	O
,	O
if	O
needed	O
,	O
a	O
washout	O
period	O
for	O
LUTS	O
-	O
BPH	B-DS
or	O
ED	B-DS
medications	O
,	O
patients	O
entered	O
a	O
4	O
week	O
placebo	O
lead	O
-	O
in	O
period	O
.	O

On	O
completion	O
,	O
patients	O
were	O
randomized	O
to	O
study	O
treatment	O
with	O
tadalafil	O
5mg	O
once	O
daily	O
for	O
12	O
weeks	O
.	O

Minor	O
differences	O
between	O
the	O
studies	O
included	O
the	O
following	O
:	O
one	O
enrolled	O
patients	O
with	O
BPH	B-DS
and	O
concomitant	O
ED	B-DS
[	O
7	O
];	O
one	O
was	O
a	O
dose	O
-	O
finding	O
study	O
in	O
which	O
tadalafil	O
was	O
administered	O
at	O
doses	O
of	O
2	O
.	O
5mg	O
,	O
5mg	O
,	O
10mg	O
,	O
20mg	O
once	O
daily	O
[	O
16	O
];	O
one	O
included	O
a	O
tadalafil	O
2	O
.	O
5mg	O
treatment	O
arm	O
[	O
7	O
];	O
and	O
one	O
included	O
an	O
additional	O
tamsulosin	O
0	O
.	O
4mg	O
treatment	O
arm	O
[	O
8	O
].	O

Design	O
of	O
the	O
four	O
randomised	O
,	O
placebo	O
-	O
controlled	O
trials	O
of	O
tadalafil	O
5mg	O
once	O
daily	O
in	O
patients	O
with	O
LUTS	O
-	O
BPH	B-DS
.	O

For	O
the	O
purposes	O
of	O
this	O
clinical	O
data	O
mining	O
analysis	O
the	O
study	O
population	O
(	O
N	O
=	O
1	O
,	O
499	O
)	O
consisted	O
solely	O
of	O
subjects	O
in	O
the	O
intent	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
population	O
who	O
had	O
been	O
allocated	O
to	O
tadalafil	O
5mg	O
once	O
daily	O
or	O
placebo	O
irrespective	O
of	O
an	O
IPSS	O
baseline	O
assessment	O
(	O
Table	O
1	O
).	O

Data	O
from	O
the	O
tadalafil	O
2	O
.	O
5mg	O
,	O
10mg	O
and	O
20mg	O
once	O
daily	O
treatment	O
groups	O
did	O
not	O
form	O
part	O
of	O
the	O
data	O
mining	O
analysis	O
,	O
as	O
these	O
doses	O
are	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
LUTS	O
-	O
BPH	B-DS
.	O

Baseline	O
characteristics	O
of	O
the	O
ITT	O
population	O
used	O
for	O
data	O
mining	O
analysis	O
.	O

Characteristics	O
*	O

Placebo	O
(	O
N	O
=	O
747	O
)	O

Tadalafil	O
5mg	O
(	O
N	O
=	O
752	O
)	O

Demographics	O

Age	O
group	O

≥	O
65	O
,	O
n	O
(%)	O

306	O
(	O
41	O
.	O
0	O
)	O

308	O
(	O
41	O
.	O
0	O
)	O

≥	O
75	O
,	O
n	O
(%)	O

74	O
(	O
9	O
.	O
9	O
)	O

68	O
(	O
9	O
.	O
0	O
)	O

Ethnicity	O
,	O
n	O
(%)	O

White	O

650	O
(	O
87	O
.	O
0	O
)	O

649	O
(	O
86	O
.	O
3	O
)	O

American	O
Indian	O
or	O
Alaska	O
Native	O

49	O
(	O
6	O
.	O
6	O
)	O

49	O
(	O
6	O
.	O
5	O
)	O

Black	O
or	O
African	O
American	O

16	O
(	O
2	O
.	O
1	O
)	O

17	O
(	O
2	O
.	O
3	O
)	O

BMI	O
≥	O
30	O
,	O
n	O
(%)	O

232	O
(	O
31	O
.	O
1	O
)	O

173	O
(	O
23	O
.	O
0	O
)	O

Mean	O
BMI	O
(	O
SD	O
),	O
kg	O
/	O
m2	O

28	O
.	O
4	O
(	O
4	O
.	O
4	O
)	O

27	O
.	O
8	O
(	O
4	O
.	O
0	O
)	O

Alcohol	O
intake	O
,	O
n	O
(%)	O

465	O
(	O
62	O
.	O
3	O
)	O

457	O
(	O
60	O
.	O
9	O
)	O

Mean	O
alcohol	O
frequency	O
(	O
drinks	O
per	O
week	O
),	O
(	O
SD	O
)	O

6	O
.	O
02	O
(	O
5	O
.	O
43	O
)	O

5	O
.	O
84	O
(	O
5	O
.	O
64	O
)	O

Smoker	O
,	O
n	O
(%)	O

99	O
(	O
13	O
.	O
3	O
)	O

90	O
(	O
12	O
.	O
0	O
)	O

LUTS	O
-	O
BPH	B-DS
history	O

Mean	O
IPSS	O
total	O
score	O
(	O
SD	O
)	O

17	O
.	O
39	O
(	O
5	O
.	O
95	O
)	O

17	O
.	O
53	O
(	O
5	O
.	O
73	O
)	O

Mean	O
IPSS	O
voiding	O
obstructive	O
subscore	O
(	O
SD	O
)	O

9	O
.	O
95	O
(	O
4	O
.	O
09	O
)	O

10	O
.	O
14	O
(	O
3	O
.	O
97	O
)	O

Mean	O
IPSS	O
storage	O
irritative	O
subscore	O
(	O
SD	O
)	O

7	O
.	O
44	O
(	O
2	O
.	O
96	O
)	O

7	O
.	O
39	O
(	O
2	O
.	O
92	O
)	O

Mean	O
IPSS	O
QoL	O
(	O
SD	O
)	O

3	O
.	O
66	O
(	O
1	O
.	O
26	O
)	O

3	O
.	O
60	O
(	O
1	O
.	O
27	O
)	O

Mean	O
BII	O
total	O
score	O
(	O
SD	O
)	O

5	O
.	O
24	O
(	O
3	O
.	O
12	O
)	O

5	O
.	O
09	O
(	O
3	O
.	O
02	O
)	O

Mean	O
PGISS	O
(	O
SD	O
)	O

4	O
.	O
04	O
(	O
1	O
.	O
0	O
)	O

3	O
.	O
99	O
(	O
0	O
.	O
97	O
)	O

LUTS	O
severity	O
,	O
n	O
(%)	O

Mild	O
-	O
moderate	O
(	O
IPSS	O
≤	O
20	O
)	O

487	O
(	O
65	O
.	O
2	O
)	O

488	O
(	O
64	O
.	O
9	O
)	O

Severe	O
(	O
IPSS	O
>	O
20	O
)	O

260	O
(	O
34	O
.	O
8	O
)	O

264	O
(	O
35	O
.	O
1	O
)	O

Mean	O
Qmax	O
(	O
SD	O
)	O
ml	O
/	O
s	O

10	O
.	O
14	O
(	O
4	O
.	O
23	O
)	O

10	O
.	O
21	O
(	O
3	O
.	O
63	O
)	O

Previous	O
LUTS	O
therapies	O
(	O
within	O
12	O
months	O
of	O
screening	O
),	O
n	O
(%)	O

α	O
-	O
blockers	O

205	O
(	O
27	O
.	O
4	O
)	O

204	O
(	O
27	O
.	O
1	O
)	O

Therapy	O
for	O
overactive	B-DS
bladder	I-DS
,	O
n	O
(%)	O

7	O
(	O
1	O
.	O
3	O
)	O

10	O
(	O
1	O
.	O
9	O
)	O

ED	B-DS
history	O

ED	B-DS
at	O
baseline	O
,	O
n	O
(%)	O

574	O
(	O
76	O
.	O
9	O
)	O

585	O
(	O
77	O
.	O
8	O
)	O

Mild	O
ED	B-DS
(	O
IIEF	O
score	O
17	O
–	O
30	O
),	O
n	O
(%)	O

147	O
/	O
574	O
(	O
25	O
.	O
6	O
)	O

148	O
/	O
585	O
(	O
25	O
.	O
3	O
)	O

Moderate	O
ED	B-DS
(	O
IIEF	O
score	O
11	O
–	O
16	O
),	O
n	O
(%)	O

340	O
/	O
574	O
(	O
59	O
.	O
2	O
)	O

339	O
/	O
585	O
(	O
57	O
.	O
9	O
)	O

Severe	O
ED	B-DS
(	O
IIEF	O
score	O
1	O
–	O
10	O
),	O
n	O
(%)	O

87	O
/	O
574	O
(	O
15	O
.	O
2	O
)	O

98	O
/	O
585	O
(	O
16	O
.	O
8	O
)	O

ED	B-DS
duration	O

<	O
3	O
months	O
,	O
n	O
(%)	O

5	O
(	O
0	O
.	O
9	O
)	O

5	O
(	O
0	O
.	O
9	O
)	O

3	O
–<	O
6	O
months	O
,	O
n	O
(%)	O

15	O
(	O
2	O
.	O
6	O
)	O

16	O
(	O
2	O
.	O
7	O
)	O

6	O
–<	O
12	O
months	O
,	O
n	O
(%)	O

57	O
(	O
9	O
.	O
9	O
)	O

61	O
(	O
10	O
.	O
4	O
)	O

≥	O
12	O
months	O
,	O
n	O
(%)	O

497	O
(	O
86	O
.	O
6	O
)	O

503	O
(	O
86	O
.	O
0	O
)	O

Etiology	O
of	O
ED	B-DS

Organic	O

206	O
(	O
27	O
.	O
6	O
)	O

195	O
(	O
25	O
.	O
9	O
)	O

Psychogenic	O

26	O
(	O
3	O
.	O
5	O
)	O

25	O
(	O
3	O
.	O
3	O
)	O

Mixed	O

225	O
(	O
30	O
.	O
1	O
)	O

258	O
(	O
34	O
.	O
3	O
)	O

Unknown	O

117	O
(	O
15	O
.	O
7	O
)	O

107	O
(	O
14	O
.	O
2	O
)	O

International	O
Index	O
of	O
Erectile	O
Function	O
(	O
IIEF	O
)	O

Mean	O
IIEF	O
-	O
EF	O
(	O
SD	O
)	O

17	O
.	O
85	O
(	O
8	O
.	O
48	O
)	O

17	O
.	O
52	O
(	O
8	O
.	O
51	O
)	O

Mean	O
IIEF	O
-	O
IS	O
(	O
SD	O
)	O

7	O
.	O
89	O
(	O
3	O
.	O
74	O
)	O

7	O
.	O
89	O
(	O
3	O
.	O
79	O
)	O

Mean	O
IIEF	O
-	O
OF	O
(	O
SD	O
)	O

7	O
.	O
03	O
(	O
3	O
.	O
17	O
)	O

6	O
.	O
60	O
(	O
3	O
.	O
26	O
)	O

Mean	O
IIEF	O
-	O
OS	O
(	O
SD	O
)	O

5	O
.	O
79	O
(	O
2	O
.	O
51	O
)	O

5	O
.	O
77	O
(	O
2	O
.	O
49	O
)	O

Mean	O
IIEF	O
-	O
SD	O
(	O
SD	O
)	O

6	O
.	O
55	O
(	O
1	O
.	O
89	O
)	O

6	O
.	O
35	O
(	O
1	O
.	O
88	O
)	O

Previous	O
ED	B-DS
therapies	O
(	O
within	O
12	O
months	O
of	O
screening	O
),	O
n	O
(%)	O

PDE	B-GP
-	I-GP
5	I-GP
inhibitor	O
,	O
n	O
(%)	O

167	O
(	O
22	O
.	O
4	O
)	O

173	O
(	O
23	O
.	O
0	O
)	O

Laboratory	O
parameters	O

Mean	O
PSA	B-GP
(	O
SD	O
),	O
ng	O
/	O
ml	O

1	O
.	O
74	O
(	O
1	O
.	O
51	O
)	O

1	O
.	O
87	O
(	O
1	O
.	O
46	O
)	O

Mean	O
total	O
testosterone	O
(	O
SD	O
),	O
ng	O
/	O
dl	O

3	O
.	O
76	O
(	O
1	O
.	O
36	O
)	O

3	O
.	O
66	O
(	O
1	O
.	O
23	O
)	O

Mean	O
free	O
testosterone	O
(	O
SD	O
),	O
ng	O
/	O
dl	O

0	O
.	O
06	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
06	O
(	O
0	O
.	O
02	O
)	O

Mean	O
bioavailable	O
testosterone	O
(	O
SD	O
),	O
ng	O
/	O
dl	O

1	O
.	O
40	O
(	O
0	O
.	O
46	O
)	O

1	O
.	O
38	O
(	O
0	O
.	O
42	O
)	O

Mean	O
%	O
bioavailable	O
testosterone	O
(	O
SD	O
)	O

39	O
.	O
26	O
(	O
12	O
.	O
07	O
)	O

39	O
.	O
70	O
(	O
11	O
.	O
09	O
)	O

Mean	O
albumin	B-GP
(	O
SD	O
),	O
g	O
/	O
dl	O

4	O
.	O
22	O
(	O
0	O
.	O
33	O
)	O

4	O
.	O
21	O
(	O
0	O
.	O
32	O
)	O

Mean	O
sex	B-GP
hormone	I-GP
binding	I-GP
globulin	I-GP
(	O
SHBG	B-GP
)	O
(	O
SD	O
)	O
nmol	O
/	O
l	O

40	O
.	O
37	O
(	O
21	O
.	O
21	O
)	O

41	O
.	O
02	O
(	O
20	O
.	O
82	O
)	O

Comorbidities	O

Diabetes	O
mellitus	O
,	O
n	O
(%)	O

94	O
(	O
12	O
.	O
6	O
)	O

98	O
(	O
13	O
.	O
0	O
)	O

Hypertension	B-DS
,	O
n	O
(%)	O

288	O
(	O
38	O
.	O
6	O
)	O

300	O
(	O
39	O
.	O
9	O
)	O

Hyperlipidaemia	O
,	O
n	O
(%)	O

152	O
(	O
20	O
.	O
3	O
)	O

183	O
(	O
24	O
.	O
3	O
)	O

Vasculitis	O
,	O
n	O
(%)	O

0	O
(	O
0	O
)	O

3	O
(	O
0	O
.	O
4	O
)	O

Ischaemic	O
heart	O
disease	O
,	O
n	O
(%)	O

44	O
(	O
5	O
.	O
9	O
)	O

43	O
(	O
5	O
.	O
7	O
)	O

Myocardial	B-DS
infarction	I-DS
,	O
n	O
(%)	O

11	O
(	O
1	O
.	O
5	O
)	O

11	O
(	O
1	O
.	O
5	O
)	O

Cardiac	O
arrhythmia	O
,	O
n	O
(%)	O

41	O
(	O
5	O
.	O
5	O
)	O

32	O
(	O
4	O
.	O
3	O
)	O

Cardiac	O
failure	O
,	O
n	O
(%)	O

6	O
(	O
0	O
.	O
8	O
)	O

5	O
(	O
0	O
.	O
7	O
)	O

Cardiomyopathy	O
,	O
n	O
(%)	O

0	O
(	O
0	O
)	O

1	O
(	O
0	O
.	O
1	O
)	O

Other	O
cardiac	O
disorders	O
,	O
n	O
(%)	O

19	O
(	O
2	O
.	O
5	O
)	O

25	O
(	O
3	O
.	O
3	O
)	O

Any	O
cardiac	O
disorder	O
,	O
n	O
(%)	O

97	O
(	O
13	O
.	O
0	O
)	O

91	O
(	O
12	O
.	O
1	O
)	O

Haemorrhagic	O
cerebrovascular	O
disorders	O
,	O
n	O
(%)	O

7	O
(	O
0	O
.	O
9	O
)	O

5	O
(	O
0	O
.	O
7	O
)	O

Ischaemic	O
cerebrovascular	O
disorders	O
,	O
n	O
(%)	O

11	O
(	O
1	O
.	O
5	O
)	O

10	O
(	O
1	O
.	O
3	O
)	O

Other	O
cerebrovascular	O
disorders	O
,	O
n	O
(%)	O

1	O
(	O
0	O
.	O
1	O
)	O

0	O
(	O
0	O
)	O

Any	O
cerebrovascular	O
disorder	O
,	O
n	O
(%)	O

11	O
(	O
1	O
.	O
5	O
)	O

10	O
(	O
1	O
.	O
3	O
)	O

Peripheral	B-DS
vascular	I-DS
thrombosis	I-DS
or	O
embolism	O
,	O
n	O
(%)	O

18	O
(	O
2	O
.	O
4	O
)	O

17	O
(	O
2	O
.	O
3	O
)	O

Miscellaneous	O
vascular	B-DS
disorder	I-DS
,	O
n	O
(%)	O

20	O
(	O
2	O
.	O
7	O
)	O

13	O
(	O
1	O
.	O
7	O
)	O

Other	O
vascular	B-DS
disorder	I-DS
,	O
n	O
(%)	O

309	O
(	O
41	O
.	O
4	O
)	O

311	O
(	O
41	O
.	O
4	O
)	O

Cardiovascular	O
disorder	O
,	O
n	O
(%)	O

342	O
(	O
45	O
.	O
8	O
)	O

344	O
(	O
45	O
.	O
7	O
)	O

Renovascular	O
disorder	O
,	O
n	O
(%)	O

0	O
(	O
0	O
)	O

0	O
(	O
0	O
)	O

Renal	B-DS
impairment	I-DS
Glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
ml	O
/	O
min	O
/	O
1	O
.	O
73m2	O

Renal	B-DS
impairment	I-DS
stage	I-DS
I	I-DS
(	O
GFR	O
≥	O
90	O
)	O
n	O
(%)	O

199	O
(	O
26	O
.	O
8	O
)	O

228	O
(	O
30	O
.	O
6	O
)	O

Renal	B-DS
impairment	I-DS
stage	I-DS
II	I-DS
(	O
GFR	O
60	O
–	O
89	O
)	O
n	O
(%)	O

327	O
(	O
44	O
.	O
0	O
)	O

368	O
(	O
49	O
.	O
3	O
)	O

Concomitant	O
medications	O

Testosterone	O
,	O
n	O
(%)	O

1	O
(	O
0	O
.	O
1	O
)	O

1	O
(	O
0	O
.	O
1	O
)	O

Mean	O
number	O
anti	O
-	O
hypertensive	O
medications	O
*	O

0	O
.	O
90	O
(	O
1	O
.	O
13	O
)	O

0	O
.	O
92	O
(	O
1	O
.	O
07	O
)	O

α	O
-	O
blockers	O
,	O
n	O
(%)	O

202	O
(	O
27	O
.	O
0	O
)	O

206	O
(	O
27	O
.	O
4	O
)	O

ß	O
-	O
blockers	O
,	O
n	O
(%)	O

92	O
(	O
12	O
.	O
3	O
)	O

114	O
(	O
15	O
.	O
2	O
)	O

Calcium	B-GP
channel	I-GP
blockers	O
,	O
n	O
(%)	O

76	O
(	O
10	O
.	O
2	O
)	O

68	O
(	O
9	O
.	O
0	O
)	O

Angiotensin	B-GP
converting	I-GP
enzyme	I-GP
inhibitors	O
,	O
n	O
(%)	O

125	O
(	O
16	O
.	O
7	O
)	O

146	O
(	O
19	O
.	O
4	O
)	O

Angiotensin	B-GP
receptor	I-GP
blockers	O
,	O
n	O
(%)	O

90	O
(	O
12	O
.	O
0	O
)	O

80	O
(	O
10	O
.	O
6	O

Diuretics	O
,	O
n	O
(%)	O

76	O
(	O
10	O
.	O
2	O
)	O

67	O
(	O
8	O
.	O
9	O
)	O

Centrally	O
-	O
acting	O
sympathomimetics	O
,	O
n	O
(%)	O

7	O
(	O
0	O
.	O
9	O
)	O

5	O
(	O
0	O
.	O
7	O
)	O

Other	O
anti	O
-	O
hypertensive	O
drugs	O
,	O
n	O
(%)	O

2	O
(	O
0	O
.	O
3	O
)	O

6	O
(	O
0	O
.	O
8	O
)	O

Selective	O
serotonin	O
reuptake	O
inhibitors	O
,	O
n	O
(%)	O

11	O
(	O
1	O
.	O
5	O
)	O

6	O
(	O
0	O
.	O
8	O
)	O

Serotonin	O
-	O
norepinephrine	O
reuptake	O
inhibitors	O
,	O
n	O
(%)	O

1	O
(	O
0	O
.	O
1	O
)	O

3	O
(	O
0	O
.	O
4	O
)	O

Antidepressants	O
,	O
n	O
(%)	O

20	O
(	O
2	O
.	O
7	O
)	O

21	O
(	O
2	O
.	O
8	O
)	O

Tricyclic	O
antidepressants	O
,	O
n	O
(%)	O

1	O
(	O
0	O
.	O
1	O
)	O

1	O
(	O
0	O
.	O
1	O
)	O

Monoamine	B-GP
oxidase	I-GP
inhibitors	O
,	O
n	O
(%)	O

0	O
(	O
0	O
)	O

0	O
(	O
0	O
)	O

Antipsychotics	O
,	O
n	O
(%)	O

5	O
(	O
0	O
.	O
7	O
)	O

3	O
(	O
0	O
.	O
4	O
)	O

Lipid	O
-	O
lowering	O
therapies	O

Statins	O
,	O
n	O
(%)	O

126	O
(	O
16	O
.	O
9	O
)	O

156	O
(	O
20	O
.	O
7	O
)	O

Other	O
lipid	O
-	O
lowering	O
drugs	O
,	O
n	O
(%)	O

28	O
(	O
3	O
.	O
7	O
)	O

32	O
(	O
4	O
.	O
3	O
)	O

Anti	O
-	O
diabetic	O
medications	O

Sulfonylureas	O
,	O
n	O
(%)	O

28	O
(	O
3	O
.	O
7	O
)	O

36	O
(	O
4	O
.	O
8	O
)	O

Alpha	B-GP
-	I-GP
glucosidase	I-GP
Inhibitors	O
,	O
n	O
(%)	O

0	O
(	O
0	O
)	O

1	O
(	O
0	O
.	O
1	O
)	O

Amylin	B-GP
analogues	O
,	O
n	O
(%)	O

0	O
(	O
0	O
)	O

0	O
(	O
0	O
)	O

Incretin	B-GP
mimetics	O
,	O
n	O
(%)	O

0	O
(	O
0	O
)	O

2	O
(	O
0	O
.	O
3	O

Dipeptidyl	B-GP
peptidase	I-GP
4	I-GP
inhibitors	O
,	O
n	O
(%)	O

2	O
(	O
0	O
.	O
3	O
)	O

6	O
(	O
0	O
.	O
8	O
)	O

Biguanides	O
,	O
n	O
(%)	O

58	O
(	O
7	O
.	O
8	O
)	O

66	O
(	O
8	O
.	O
8	O
)	O

Meglitinides	O
,	O
n	O
(%)	O

2	O
(	O
0	O
.	O
3	O
)	O

1	O
(	O
0	O
.	O
1	O
)	O

Thiazlidinediones	O
,	O
n	O
(%)	O

8	O
(	O
1	O
.	O
1	O
)	O

10	O
(	O
1	O
.	O
3	O
)	O

CYP3A4	B-GP
Inhibitors	O
,	O
n	O
(%)	O

88	O
(	O
11	O
.	O
8	O
)	O

101	O
(	O
13	O
.	O
4	O
)	O

Treatment	O
compliance	O

Hypertension	B-DS
treatment	O
phase	O
,	O
n	O
(%)	O

285	O
(	O
38	O
.	O
2	O
)	O

309	O
(	O
41	O
.	O
1	O
)	O

Oral	O
agent	O
,	O
n	O
(%)	O

70	O
(	O
9	O
.	O
4	O
)	O

79	O
(	O
10	O
.	O
5	O
)	O

Oral	O
agent	O
treatment	O
phase	O
,	O
n	O
(%)	O

71	O
(	O
9	O
.	O
5	O
)	O

79	O
(	O
10	O
.	O
5	O
)	O

*	O
Eight	O
derived	O
variables	O
defined	O
in	O
the	O
SAP	O
(	O
Cluster	O
cardiovascular	O
drugs	O
,	O
cluster	O
cerebrovascular	O
drugs	O
,	O
cluster	O
cardiovascular	B-DS
diseases	I-DS
,	O
cluster	O
cerebrovascular	B-DS
diseases	I-DS
,	O
cluster	O
anti	O
-	O
hypertensive	O
drugs	O
,	O
cluster	O
anti	O
-	O
psychotic	O
drugs	O
,	O
cluster	O
anti	O
-	O
diabetic	O
drugs	O
,	O
cluster	O
lipid	O
-	O
lowering	O
drugs	O
)	O
were	O
included	O
in	O
each	O
assessment	O
,	O
which	O
yields	O
106	O
variables	O
.	O

The	O
inclusion	O
of	O
TRT	O
as	O
a	O
variable	O
,	O
which	O
is	O
implicit	O
in	O
our	O
evaluation	O
,	O
gives	O
107	O
variables	O
in	O
total	O
.	O

Percent	O
missing	O
values	O
were	O
as	O
follows	O
:	O
Testosterone	O
(	O
baseline	O
),	O
Free	O
testosterone	O
[	O
18	O
],	O
%	O
free	O
testosterone	O
,	O
Bioavailable	O
testosterone	O
,	O
%	O
bioavailable	O
testosterone	O
=	O
79	O
%;	O
PSA	B-GP
(	O
baseline	O
)	O
=	O
70	O
%;	O
Alcohol	O
frequency	O
=	O
38	O
%;	O
SHBG	B-GP
(	O
baseline	O
)	O
=	O
33	O
%;	O
PGISS	O
baseline	O
,	O
Previous	O
overactive	B-DS
bladder	I-DS
therapy	O
(	O
Y	O
/	O
N	O
)	O
=	O
28	O
%;	O
Qmax	O
,	O
ED	B-DS
duration	O
,	O
ED	B-DS
aetiology	O
,	O
ED	B-DS
severity	O
=	O
23	O
%;	O
IIEF	O
baseline	O
severity	O
,	O
IIEF	O
-	O
EF	O
(	O
baseline	O
),	O
IIEF	O
-	O
OF	O
(	O
baseline	O
),	O
IIEF	O
-	O
OS	O
(	O
baseline	O
),	O
IIEF	O
-	O
SD	O
(	O
baseline	O
),	O
IIEF	O
-	O
IS	O
(	O
baseline	O
)	O
=	O
14	O
%;	O
Albumin	B-GP
(	O
baseline	O
)	O
=	O
2	O
%;	O
Renal	B-DS
impairment	I-DS
I	I-DS
,	O
Renal	B-DS
impairment	I-DS
II	I-DS
,	O
Renal	B-DS
impairment	I-DS
I	I-DS
(≥	O
80	O
),	O
Renal	B-DS
impairment	I-DS
II	I-DS
(≥	O
90	O
)	O
=	O
1	O
%.	O

*	O
prior	O
α	O
-	O
blocking	O
agents	O
,	O
β	O
-	O
blockers	O
,	O
calcium	B-GP
channels	I-GP
blockers	O
,	O
angiotensin	B-GP
converting	I-GP
enzyme	I-GP
inhibitors	O
,	O
angiotensin	B-GP
receptor	I-GP
blockers	O
and	O
diuretics	O
.	O

IPSS	O
,	O
IPSS	O
QoL	O
,	O
and	O
BPH	B-DS
Impact	O
Index	O
(	O
BII	O
)	O
were	O
assessed	O
in	O
each	O
of	O
the	O
four	O
studies	O
at	O
baseline	O
(	O
after	O
the	O
4	O
week	O
placebo	O
lead	O
-	O
in	O
period	O
following	O
randomization	O
)	O
and	O
after	O
12	O
weeks	O
treatment	O
(	O
primary	O
endpoint	O
).	O

Patient	O
Global	O
Impression	O
of	O
Improvement	O
(	O
PGI	O
-	O
I	O
)	O
was	O
evaluated	O
at	O
baseline	O
and	O
endpoint	O
in	O
three	O
of	O
the	O
four	O
studies	O
so	O
as	O
to	O
assess	O
the	O
impression	O
of	O
change	O
in	O
urinary	O
symptoms	O
[	O
6	O
;	O
7	O
;	O
8	O
].	O

Overall	O
,	O
107	O
baseline	O
characteristics	O
were	O
included	O
in	O
the	O
clinical	O
data	O
mining	O
analysis	O
(	O
Table	O
1	O
).	O

Baseline	O
characteristics	O
were	O
categorized	O
as	O
key	O
or	O
supportive	O
and	O
selected	O
on	O
the	O
basis	O
of	O
clinical	O
input	O
from	O
study	O
authors	O
that	O
was	O
derived	O
from	O
knowledge	O
of	O
the	O
published	O
literature	O
and	O
clinical	O
experience	O
.	O

All	O
IPSS	O
,	O
IPSS	O
QoL	O
and	O
BII	O
baseline	O
scores	O
and	O
their	O
subscores	O
were	O
key	O
characteristics	O
,	O
in	O
addition	O
to	O
age	O
(<	O
65	O
or	O
≥	O
65	O
years	O
),	O
previous	O
LUTS	O
therapy	O
and	O
a	O
history	O
of	O
ED	B-DS
(	O
Table	O
1	O
).	O

Key	O
characteristics	O
were	O
expected	O
to	O
be	O
predictive	O
for	O
a	O
response	O
to	O
treatment	O
.	O

Two	O
primary	O
and	O
6	O
secondary	O
definitions	O
of	O
response	O
were	O
used	O
(	O
Table	O
2	O
).	O

The	O
primary	O
responder	O
definitions	O
were	O
considered	O
of	O
equal	O
importance	O
and	O
both	O
were	O
based	O
on	O
Minimal	O
Clinically	O
Important	O
Differences	O
(‘	O
overall	O
’	O
or	O
‘	O
severity	O
MCID	O
’),	O
a	O
concept	O
validated	O
using	O
an	O
anchor	O
-	O
based	O
approach	O
[	O
19	O
].	O

MCID	O
is	O
a	O
threshold	O
that	O
represents	O
a	O
CMI	O
in	O
patients	O
’	O
health	O
-	O
related	O
QoL	O
as	O
perceived	O
by	O
the	O
patient	O
[	O
24	O
].	O
‘	O
Overall	O
MCID	O
’	O
was	O
defined	O
as	O
an	O
improvement	O
in	O
IPSS	O
total	O
score	O
of	O
≥	O
3	O
for	O
all	O
patients	O
(	O
overall	O
response	O
)	O
and	O
‘	O
severity	O
MCID	O
’	O
defined	O
as	O
an	O
improvement	O
in	O
IPSS	O
total	O
score	O
of	O
≥	O
2	O
for	O
patients	O
with	O
mild	O
-	O
to	O
-	O
moderate	O
LUTS	O
and	O
of	O
6	O
for	O
those	O
with	O
severe	O
LUTS	O
[	O
14	O
;	O
19	O
].	O

Secondary	O
definitions	O
of	O
response	O
were	O
ranked	O
in	O
order	O
of	O
decreasing	O
validation	O
,	O
although	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
they	O
have	O
not	O
been	O
subject	O
to	O
formal	O
validation	O
.	O

Definition	O
of	O
treatment	O
response	O
on	O
the	O
IPSS	O
,	O
BII	O
and	O
PGI	O
-	O
I	O
after	O
12	O
weeks	O
treatment	O
with	O
tadalafil	O
or	O
placebo	O
as	O
used	O
in	O
the	O
clinical	O
data	O
mining	O
analysis	O
.	O

Instruments	O

Primary	O
objectives	O

IPSS	O

Reduction	O
of	O
≥	O
3	O
points	O
in	O
overall	O
IPSS	O
score	O
[	O
19	O
;	O
20	O
]	O

Improvement	O
of	O
≥	O
2	O
points	O
in	O
patients	O
with	O
IPSS	O
baseline	O
score	O
<	O
20	O
and	O
of	O
≥	O
6	O
points	O
in	O
patients	O
with	O
baseline	O
score	O
≥	O
20	O
[	O
19	O
]	O

Secondary	O
Objectives	O

IPSS	O
QoL	O

Reduction	O
of	O
≥	O
1	O
point	O
in	O
IPSS	O
QoL	O
[	O
21	O
]	O

IPSS	O

≥	O
25	O
%	O
improvement	O
in	O
IPSS	O
[	O
22	O
]	O

IPSS	O
total	O
score	O
<	O
12	O
in	O
patients	O
with	O
prior	O
score	O
of	O
≥	O
12	O

BII	O

Total	O
score	O
of	O
<	O
9	O

Reduction	O
of	O
>	O
1	O
point	O
[	O
19	O
]	O

PGI	O
-	O
I	O

Any	O
improvement	O
from	O
baseline	O
[	O
23	O
]	O

BII	O
,	O
BPH	B-DS
Impact	O
Index	O
;	O
IPSS	O
,	O
International	O
Prostate	O
Symptom	O
Score	O
;	O
PGI	O
-	O
I	O
,	O
Patient	O
Global	O
Impression	O
of	O
Improvement	O
;	O
QoL	O
,	O
quality	O
of	O
life	O
.	O

Consistent	O
with	O
best	O
practice	O
,	O
missing	O
values	O
were	O
documented	O
and	O
data	O
were	O
screened	O
for	O
outliers	O
[	O
17	O
].	O

Because	O
of	O
minor	O
differences	O
in	O
study	O
design	O
,	O
data	O
were	O
not	O
necessarily	O
available	O
on	O
all	O
baseline	O
variables	O
.	O

Outliers	O
were	O
defined	O
as	O
data	O
points	O
outside	O
the	O
range	O
of	O
[	O
Q1	O
–	O
1	O
.	O
5	O
x	O
IQR	O
,	O
Q3	O
+	O
1	O
.	O
5	O
x	O
IQR	O
],	O
where	O
Q1	O
and	O
Q3	O
were	O
the	O
first	O
and	O
third	O
quartiles	O
and	O
IQR	O
the	O
inter	O
-	O
quartile	O
range	O
,	O
respectively	O
.	O

No	O
imputation	O
was	O
conducted	O
for	O
missing	O
values	O
.	O

Implementation	O

Bias	O
stemming	O
from	O
the	O
desire	O
to	O
achieve	O
100	O
%	O
prediction	O
accuracy	O
was	O
controlled	O
by	O
following	O
the	O
pre	O
-	O
specified	O
SAP	O
as	O
described	O
earlier	O
,	O
which	O
was	O
approved	O
by	O
all	O
study	O
authors	O
and	O
peer	O
reviewed	O
by	O
Lilly	O
data	O
mining	O
experts	O
prior	O
to	O
programming	O
.	O

A	O
non	O
-	O
clinical	O
benchmark	O
data	O
mining	O
dataset	O
was	O
used	O
for	O
program	O
development	O
.	O

Results	O
from	O
the	O
clinical	O
dataset	O
were	O
produced	O
after	O
program	O
peer	O
review	O
,	O
which	O
was	O
carried	O
out	O
by	O
an	O
independent	O
statistician	O
.	O

All	O
modifications	O
of	O
the	O
analysis	O
after	O
this	O
run	O
were	O
reported	O
as	O
post	O
-	O
hoc	O
.	O

LR	O
and	O
DT	O
models	O
were	O
selected	O
as	O
our	O
data	O
mining	O
models	O
as	O
both	O
can	O
be	O
presented	O
visually	O
and	O
translated	O
into	O
easy	O
decision	O
rules	O
or	O
scores	O
for	O
practical	O
use	O
in	O
medical	O
applications	O
[	O
25	O
;	O
26	O
;	O
27	O
]	O
(	O
S1	O
Technical	O
Appendix	O
).	O

To	O
avoid	O
bias	O
from	O
an	O
overly	O
complex	O
prediction	O
model	O
when	O
a	O
simple	O
one	O
would	O
suffice	O
[	O
17	O
],	O
we	O
compared	O
all	O
models	O
against	O
SDRs	O
.	O

These	O
were	O
implemented	O
using	O
the	O
DT	O
algorithm	O
that	O
was	O
allowed	O
to	O
generate	O
a	O
single	O
decision	O
.	O

In	O
addition	O
,	O
SVM	O
[	O
28	O
]	O
(	O
S2	O
Technical	O
Appendix	O
)	O
and	O
RF	O
classifiers	O
[	O
29	O
]	O
were	O
applied	O
to	O
obtain	O
estimates	O
for	O
best	O
prediction	O
accuracy	O
(	O
S3	O
Technical	O
Appendix	O
).	O

The	O
split	O
set	O
evaluation	O
method	O
was	O
used	O
to	O
estimate	O
prediction	O
accuracy	O
on	O
unknown	O
data	O
.	O

To	O
this	O
end	O
,	O
the	O
database	O
was	O
randomly	O
split	O
into	O
training	O
(	O
60	O
%	O
of	O
the	O
database	O
)	O
and	O
test	O
(	O
40	O
%	O
of	O
the	O
database	O
)	O
subsets	O
(	O
Fig	O
2	O
).	O

Then	O
LR	O
,	O
DT	O
,	O
SVM	O
,	O
RF	O
and	O
SDR	O
models	O
were	O
generated	O
on	O
the	O
training	O
subset	O
and	O
used	O
to	O
predict	O
the	O
response	O
of	O
patients	O
in	O
the	O
held	O
-	O
out	O
test	O
subset	O
.	O

Prediction	O
models	O
were	O
generated	O
for	O
the	O
tadalafil	O
5mg	O
once	O
daily	O
and	O
placebo	O
groups	O
.	O

Prediction	O
accuracy	O
was	O
measured	O
by	O
sensitivity	O
(	O
true	O
positives	O
)	O
and	O
specificity	O
(	O
true	O
negatives	O
),	O
for	O
which	O
95	O
%	O
confidence	O
intervals	O
were	O
calculated	O
.	O

Sensitivity	O
and	O
specificity	O
were	O
calculated	O
as	O
follows	O
:	O
Sensitivity	O
=	O
TPTP	O
+	O
FP	O
;	O
Specificity	O
=	O
TNTN	O
+	O
FN	O

In	O
the	O
equation	O
,	O
TP	O
and	O
TN	O
denote	O
the	O
true	O
positive	O
and	O
true	O
negative	O
predictions	O
and	O
FP	O
and	O
FN	O
denote	O
the	O
false	O
positive	O
and	O
false	O
negative	O
predictions	O
on	O
the	O
test	O
split	O
.	O

Data	O
Analysis	O
Flow	O
.	O

Receiver	O
Operating	O
Curve	O
(	O
ROC	O
)	O
analysis	O
was	O
used	O
to	O
identify	O
optimal	O
prediction	O
models	O
lying	O
on	O
the	O
ROC	O
surface	O
[	O
30	O
]	O
(	O
Fig	O
2	O
).	O

For	O
ROC	O
curve	O
interpretation	O
we	O
adopted	O
a	O
systematic	O
approach	O
in	O
which	O
models	O
on	O
the	O
ROC	O
surface	O
were	O
first	O
documented	O
by	O
their	O
respective	O
sensitivity	O
and	O
specificity	O
,	O
after	O
which	O
the	O
model	O
on	O
the	O
ROC	O
surface	O
that	O
gave	O
equal	O
weight	O
to	O
false	O
positive	O
and	O
false	O
negative	O
errors	O
was	O
discussed	O
in	O
detail	O
.	O

For	O
the	O
primary	O
objectives	O
,	O
the	O
resulting	O
sensitivity	O
and	O
specificity	O
was	O
then	O
compared	O
to	O
the	O
Q1	O
–	O
Q3	O
range	O
of	O
1	O
,	O
000	O
repeated	O
runs	O
of	O
the	O
60	O
:	O
40	O
split	O
set	O
evaluation	O
to	O
ensure	O
consistency	O
(	O
non	O
-	O
random	O
data	O
)	O
(	O
S4	O
Technical	O
Appendix	O
).	O

Additionally	O
,	O
these	O
results	O
were	O
compared	O
with	O
results	O
obtained	O
from	O
1	O
,	O
000	O
repeated	O
runs	O
with	O
a	O
randomly	O
permuted	O
response	O
variable	O
(	O
random	O
data	O
).	O

Finally	O
,	O
sensitivity	O
and	O
specificity	O
findings	O
were	O
compared	O
against	O
an	O
80	O
%	O
cut	O
-	O
off	O
,	O
representing	O
a	O
performance	O
threshold	O
suitable	O
for	O
routine	O
clinical	O
use	O
.	O

All	O
analyses	O
were	O
programmed	O
in	O
R	O
2	O
.	O
15	O
.	O
1	O
using	O
packages	O
rpart	O
(	O
3	O
.	O
1	O
–	O
53	O
;	O
for	O
DTs	O
)	O
[	O
31	O
]	O
e1017	O
(	O
1	O
.	O
6	O
–	O
1	O
;	O
for	O
SVM	O
)	O
[	O
32	O
]	O
and	O
Random	O
Forest	O
(	O
4	O
.	O
6	O
–	O
7	O
;	O
for	O
RFs	O
)	O
[	O
33	O
].	O

Post	O
-	O
hoc	O
sensitivity	O
analyses	O
were	O
conducted	O
to	O
determine	O
whether	O
or	O
not	O
excluding	O
a	O
minimised	O
combination	O
of	O
characteristics	O
affected	O
primarily	O
by	O
missing	O
data	O
would	O
allow	O
the	O
generation	O
of	O
improved	O
models	O
(	O
S5	O
Technical	O
Appendix	O
).	O

Again	O
,	O
emphasis	O
was	O
placed	O
on	O
those	O
models	O
being	O
optimal	O
when	O
false	O
positive	O
and	O
false	O
negative	O
errors	O
were	O
of	O
equal	O
importance	O
(	O
i	O
.	O
e	O
.	O
a	O
sensitivity	O
and	O
specificity	O
threshold	O
of	O
>	O
80	O
%).	O

Results	O

Overall	O
findings	O

Analyses	O
were	O
based	O
on	O
pooled	O
data	O
from	O
four	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trials	O
that	O
primarily	O
compared	O
the	O
effect	O
of	O
12	O
weeks	O
treatment	O
with	O
tadalafil	O
5mg	O
once	O
daily	O
with	O
placebo	O
on	O
symptomatic	O
LUTS	O
improvement	O
in	O
men	O
with	O
LUTS	O
-	O
BPH	B-DS
.	O

Baseline	O
characteristics	O
of	O
patients	O
in	O
the	O
two	O
treatment	O
groups	O
were	O
well	O
balanced	O
(	O
Table	O
1	O
).	O

There	O
was	O
negligible	O
heterogeneity	O
across	O
the	O
four	O
studies	O
.	O

The	O
complete	O
ITT	O
population	O
was	O
used	O
in	O
all	O
our	O
models	O
.	O

However	O
,	O
depending	O
on	O
the	O
algorithm	O
,	O
there	O
were	O
exclusions	O
due	O
to	O
missing	O
response	O
or	O
incomplete	O
data	O
from	O
the	O
run	O
.	O

LR	O
,	O
SVM	O
and	O
RF	O
implementation	O
could	O
not	O
be	O
used	O
with	O
incomplete	O
patient	O
records	O
,	O
whereas	O
DTs	O
were	O
able	O
to	O
handle	O
missing	O
predictor	O
,	O
but	O
not	O
missing	O
response	O
variable	O
information	O
,	O
by	O
using	O
‘	O
surrogate	O
splits	O
’,	O
for	O
which	O
we	O
allowed	O
5	O
.	O

Post	O
-	O
hoc	O
sensitivity	O
analysis	O
was	O
used	O
to	O
explore	O
the	O
influence	O
of	O
missing	O
data	O
on	O
the	O
primary	O
result	O
.	O

The	O
set	O
of	O
predictors	O
was	O
reduced	O
such	O
that	O
a	O
sufficient	O
number	O
of	O
complete	O
records	O
were	O
available	O
to	O
the	O
logistic	O
regression	O
,	O
SVM	O
and	O
RF	O
training	O
algorithms	O
.	O

In	O
the	O
end	O
,	O
all	O
patients	O
included	O
in	O
the	O
ITT	O
population	O
were	O
available	O
for	O
inclusion	O
in	O
the	O
data	O
mining	O
algorithms	O
and	O
no	O
patient	O
was	O
excluded	O
for	O
reasons	O
other	O
than	O
technical	O
ones	O
.	O

Based	O
on	O
these	O
data	O
,	O
the	O
output	O
from	O
our	O
clinical	O
data	O
mining	O
analysis	O
did	O
not	O
find	O
sufficiently	O
good	O
predictors	O
of	O
treatment	O
response	O
to	O
placebo	O
or	O
tadalafil	O
.	O

None	O
of	O
the	O
107	O
pre	O
-	O
selected	O
baseline	O
characteristics	O
achieved	O
a	O
combined	O
sensitivity	O
and	O
specificity	O
of	O
>	O
80	O
%	O
that	O
would	O
enable	O
reliable	O
allocation	O
of	O
an	O
individual	O
patient	O
to	O
either	O
the	O
tadalafil	O
responder	O
or	O
non	O
-	O
responder	O
group	O
.	O

As	O
the	O
detailed	O
results	O
presented	O
below	O
demonstrate	O
,	O
IPSS	O
baseline	O
(	O
mild	O
/	O
moderate	O
vs	O
.	O
severe	O
group	O
)	O
for	O
both	O
placebo	O
and	O
tadalafil	O
5mg	O
once	O
daily	O
was	O
found	O
several	O
times	O
on	O
the	O
ROC	O
surface	O
and	O
generated	O
the	O
highest	O
combined	O
sensitivity	O
and	O
specificity	O
of	O
70	O
%	O
and	O
~	O
50	O
%,	O
respectively	O
,	O
for	O
all	O
analyses	O
.	O

Significance	O
of	O
outliers	O

Outliers	O
were	O
assessed	O
in	O
this	O
clinical	O
data	O
mining	O
study	O
but	O
were	O
not	O
removed	O
for	O
the	O
reasons	O
described	O
earlier	O
.	O

The	O
assessment	O
of	O
outliers	O
led	O
to	O
relatively	O
few	O
observations	O
.	O

It	O
is	O
worth	O
noting	O
that	O
3	O
baseline	O
characteristics	O
had	O
skewed	O
distributions	O
.	O

These	O
were	O
maximum	O
urinary	O
flow	O
rate	O
(	O
Qmax	O
),	O
body	O
mass	O
index	O
(	O
BMI	O
),	O
and	O
frequency	O
of	O
alcohol	O
intake	O
,	O
all	O
of	O
which	O
had	O
>	O
23	O
outliers	O
in	O
the	O
upper	O
range	O
of	O
their	O
respective	O
scales	O
.	O

Full	O
outlier	O
results	O
are	O
given	O
in	O
the	O
accompanying	O
Supporting	O
Information	O
(	O
S6	O
Technical	O
Appendix	O
).	O

Primary	O
Objectives	O

In	O
our	O
ROC	O
curve	O
analyses	O
,	O
models	O
on	O
the	O
ROC	O
surface	O
represented	O
an	O
optimal	O
trade	O
-	O
off	O
between	O
prediction	O
errors	O
(	O
false	O
positive	O
vs	O
.	O
false	O
negative	O
predictions	O
).	O

Here	O
we	O
describe	O
results	O
from	O
the	O
model	O
in	O
which	O
we	O
observed	O
an	O
equal	O
trade	O
-	O
off	O
between	O
both	O
errors	O
as	O
determined	O
by	O
ROC	O
curve	O
analysis	O
.	O

Only	O
SDR	O
models	O
were	O
obtained	O
for	O
the	O
pre	O
-	O
specified	O
analyses	O
predicting	O
‘	O
severity	O
MCID	O
’	O
and	O
‘	O
overall	O
MCID	O
’	O
response	O
.	O

A	O
reduction	O
of	O
≥	O
3	O
points	O
in	O
overall	O
IPSS	O
score	O
,	O
or	O
improvement	O
of	O
≥	O
2	O
points	O
in	O
patients	O
with	O
IPSS	O
baseline	O
score	O
<	O
20	O
and	O
of	O
≥	O
6	O
points	O
in	O
patients	O
with	O
baseline	O
score	O
≥	O
20	O
were	O
the	O
primary	O
objectives	O
.	O

Prediction	O
of	O
‘	O
severity	O
MCID	O
’	O
response	O
in	O
the	O
tadalafil	O
5mg	O
once	O
daily	O
group	O
produced	O
SDR	O
models	O
on	O
the	O
ROC	O
surface	O
for	O
IPSS	O
severity	O
group	O
(	O
mild	O
/	O
moderate	O
vs	O
.	O
severe	O
)	O
and	O
IPSS	O
voiding	O
subscore	O
only	O
(	O
Table	O
3	O
).	O

The	O
model	O
with	O
equal	O
importance	O
for	O
FP	O
and	O
FN	O
error	O
was	O
based	O
on	O
IPSS	O
severity	O
group	O
.	O

These	O
results	O
(	O
using	O
this	O
model	O
)	O
were	O
supported	O
by	O
repeat	O
evaluations	O
,	O
which	O
lay	O
within	O
the	O
Q1	O
–	O
Q3	O
ranges	O
for	O
sensitivity	O
and	O
specificity	O
of	O
68	O
–	O
72	O
%	O
and	O
45	O
–	O
50	O
%,	O
respectively	O
.	O

Q1	O
–	O
Q3	O
ranges	O
for	O
random	O
data	O
were	O
34	O
–	O
66	O
%	O
for	O
sensitivity	O
,	O
and	O
as	O
such	O
did	O
not	O
overlap	O
with	O
the	O
runs	O
on	O
non	O
-	O
random	O
data	O
,	O
and	O
34	O
–	O
66	O
%	O
for	O
specificity	O
.	O

For	O
subjects	O
in	O
the	O
mild	O
/	O
moderate	O
group	O
,	O
this	O
model	O
predicted	O
a	O
positive	O
‘	O
severity	O
MCID	O
’	O
response	O
.	O

Primary	O
results	O
for	O
both	O
treatment	O
groups	O
.	O

Severity	O
MCID	O

Treatment	O
group	O

Sensitivity	O
%	O
(	O
95	O
%	O
CI	O
)	O

Specificity	O
%	O
(	O
95	O
%	O
CI	O
)	O

Tadalafil	O
5mg	O

IPSS	O
baseline	O
(	O
mild	O
/	O
moderate	O
vs	O
.	O
severe	O
)*	O

70	O
(	O
63	O
,	O
76	O
)	O

50	O
(	O
40	O
,	O
60	O
)	O

IPSS	O
voiding	O
/	O
obstructive	O
subscore	O

97	O
(	O
94	O
,	O
99	O
)	O

7	O
(	O
3	O
,	O
15	O
)	O

Placebo	O

Bioavailable	O
testosterone	O

13	O
(	O
8	O
,	O
19	O
)	O

91	O
(	O
85	O
,	O
95	O
)	O

ED	B-DS
aetiology	O

49	O
(	O
41	O
,	O
57	O
)	O

61	O
(	O
52	O
,	O
69	O
)	O

IPSS	O
baseline	O
(	O
mild	O
/	O
moderate	O
vs	O
.	O
severe	O
)*	O

74	O
(	O
66	O
,	O
80	O
)	O

39	O
(	O
30	O
,	O
47	O
)	O

Cluster	O
lipid	O
-	O
lowering	O
medications	O

88	O
(	O
82	O
,	O
93	O
)	O

23	O
(	O
16	O
,	O
31	O
)	O

Antidepressants	O
(	O
Y	O
/	O
N	O
)	O

98	O
(	O
94	O
,	O
100	O
)	O

5	O
(	O
2	O
,	O
10	O
)	O

5	B-GP
-	I-GP
α	I-GP
-	I-GP
reductase	I-GP
inhibitors	O
(	O
Y	O
/	O
N	O
)	O

99	O
(	O
96	O
,	O
100	O
)	O

2	O
(	O
0	O
,	O
6	O
)	O

Overall	O
MCID	O

Tadalafil	O
5mg	O

Ethnicity	O

9	O
(	O
5	O
,	O
14	O
)	O

98	O
(	O
92	O
,	O
100	O
)	O

IPSS	O
baseline	O
(	O
mild	O
/	O
moderate	O
vs	O
.	O
severe	O
)	O

38	O
(	O
32	O
,	O
45	O
)	O

71	O
(	O
61	O
,	O
80	O
)	O

IPSS	O
voiding	O
obstructive	O
subscore	O
*	O

96	O
(	O
92	O
,	O
98	O
)	O

20	O
(	O
12	O
,	O
29	O
)	O

Placebo	O

Cluster	O
antidiabetic	O
drugs	O

11	O
(	O
6	O
,	O
16	O
)	O

95	O
(	O
89	O
,	O
98	O
)	O

IPSS	O
baseline	O
(	O
mild	O
/	O
moderate	O
vs	O
.	O
severe	O
)	O

40	O
(	O
33	O
,	O
48	O
)	O

73	O
(	O
65	O
,	O
81	O
)	O

Alcohol	O
use	O
(	O
Y	O
/	O
N	O
)	O

45	O
(	O
37	O
,	O
53	O
)	O

70	O
(	O
61	O
,	O
77	O
)	O

IPSS	O
voiding	O
/	O
obstructive	O
subscore	O
*	O

94	O
(	O
89	O
,	O
97	O
)	O

23	O
(	O
16	O
,	O
31	O
)	O

*	O
Model	O
on	O
ROC	O
surface	O
with	O
best	O
performance	O
if	O
false	O
positive	O
and	O
false	O
negative	O
errors	O
are	O
equally	O
important	O
.	O

CI	O
,	O
confidence	O
interval	O
;	O
ED	B-DS
,	O
erectile	B-DS
dysfunction	I-DS
;	O
IPSS	O
,	O
International	O
Prostate	O
Symptom	O
Score	O
;	O
MCID	O
,	O
Minimal	O
Clinically	O
Important	O
Differences	O
;	O
N	O
,	O
no	O
;	O
PSA	B-GP
,	O
prostate	B-GP
specific	I-GP
antigen	I-GP
;	O
ROC	O
,	O
Receiver	O
Operating	O
Curve	O
;	O
Y	O
,	O
yes	O
.	O

‘	O
Severity	O
MCID	O
’	O
response	O
in	O
the	O
placebo	O
group	O
was	O
predicted	O
by	O
six	O
SDR	O
models	O
lying	O
on	O
the	O
ROC	O
surface	O
that	O
included	O
bioavailable	O
testosterone	O
,	O
ED	B-DS
etiology	O
,	O
IPSS	O
severity	O
,	O
cluster	O
of	O
lipid	O
-	O
lowering	O
medications	O
,	O
antidepressants	O
,	O
and	O
use	O
of	O
5	B-GP
-	I-GP
α	I-GP
-	I-GP
reductase	I-GP
inhibitors	O
(	O
Table	O
3	O
).	O

Again	O
,	O
IPSS	O
severity	O
achieved	O
the	O
combination	O
of	O
best	O
sensitivity	O
and	O
specificity	O
when	O
positive	O
and	O
negative	O
prediction	O
errors	O
were	O
of	O
equal	O
importance	O
.	O

The	O
Q1	O
–	O
Q3	O
range	O
for	O
all	O
evaluations	O
was	O
71	O
–	O
74	O
%	O
for	O
sensitivity	O
and	O
39	O
–	O
44	O
%	O
for	O
specificity	O
,	O
while	O
random	O
data	O
yielded	O
sensitivities	O
of	O
32	O
–	O
65	O
%	O
and	O
specificities	O
of	O
36	O
–	O
68	O
%.	O

Again	O
,	O
there	O
was	O
no	O
overlap	O
with	O
evaluations	O
on	O
non	O
-	O
random	O
data	O
,	O
increasing	O
confidence	O
that	O
the	O
effect	O
was	O
not	O
simply	O
due	O
to	O
random	O
effect	O
.	O

This	O
model	O
also	O
predicted	O
a	O
positive	O
‘	O
severity	O
MCID	O
’	O
response	O
for	O
subjects	O
in	O
the	O
mild	O
/	O
moderate	O
group	O
.	O

SDR	O
models	O
predicting	O
‘	O
overall	O
MCID	O
’	O
response	O
in	O
the	O
tadalafil	O
5mg	O
once	O
daily	O
group	O
were	O
based	O
on	O
ethnicity	O
,	O
IPSS	O
severity	O
,	O
and	O
IPSS	O
voiding	O
subscores	O
(	O
Table	O
3	O
).	O

Here	O
,	O
the	O
IPSS	O
voiding	O
subscore	O
SDR	O
model	O
achieved	O
optimal	O
predictions	O
when	O
false	O
positive	O
errors	O
were	O
assumed	O
to	O
have	O
the	O
same	O
importance	O
as	O
false	O
negative	O
errors	O
.	O

Q1	O
–	O
Q3	O
ranges	O
were	O
77	O
–	O
96	O
%	O
for	O
sensitivity	O
and	O
13	O
–	O
29	O
%	O
for	O
specificity	O
.	O

For	O
random	O
data	O
these	O
were	O
8	O
–	O
89	O
%	O
for	O
sensitivity	O
,	O
respectively	O
,	O
and	O
11	O
–	O
91	O
%	O
for	O
specificity	O
,	O
respectively	O
.	O

‘	O
Overall	O
MCID	O
’	O
for	O
the	O
placebo	O
group	O
was	O
best	O
predicted	O
by	O
SDR	O
models	O
that	O
included	O
cluster	O
of	O
anti	O
-	O
diabetic	O
drugs	O
,	O
IPSS	O
severity	O
,	O
alcohol	O
usage	O
,	O
and	O
IPSS	O
voiding	O
subscore	O
(	O
Table	O
3	O
).	O

Giving	O
equal	O
importance	O
to	O
false	O
positives	O
and	O
to	O
false	O
negatives	O
,	O
IPSS	O
voiding	O
scores	O
obtained	O
the	O
best	O
predictions	O
.	O

Subjects	O
with	O
an	O
IPSS	O
voiding	O
subscore	O
>	O
5	O
.	O
5	O
were	O
predicted	O
to	O
have	O
a	O
higher	O
likelihood	O
of	O
‘	O
overall	O
MCID	O
’	O
response	O
.	O

Q1	O
–	O
Q3	O
ranges	O
for	O
this	O
model	O
in	O
all	O
evaluations	O
were	O
93	O
–	O
95	O
%	O
for	O
sensitivities	O
and	O
19	O
–	O
23	O
%	O
for	O
specificities	O
.	O

The	O
corresponding	O
results	O
for	O
random	O
data	O
were	O
10	O
–	O
88	O
%	O
for	O
sensitivities	O
and	O
13	O
–	O
90	O
%	O
for	O
specificities	O
.	O

The	O
IPSS	O
severity	O
categories	O
(	O
mild	O
/	O
moderate	O
vs	O
.	O
severe	O
)	O
based	O
on	O
a	O
cut	O
-	O
off	O
of	O
20	O
were	O
part	O
of	O
the	O
ROC	O
surface	O
regardless	O
of	O
MCID	O
definition	O
and	O
regardless	O
of	O
treatment	O
group	O
(	O
i	O
.	O
e	O
.	O
tadalafil	O
5mg	O
once	O
daily	O
or	O
placebo	O
).	O

IPSS	O
voiding	O
subscore	O
was	O
found	O
on	O
the	O
ROC	O
surface	O
for	O
‘	O
overall	O
MCID	O
’	O
prediction	O
.	O

Secondary	O
Objectives	O

Estimates	O
for	O
sensitivities	O
and	O
specificities	O
for	O
each	O
of	O
the	O
secondary	O
objectives	O
for	O
the	O
two	O
treatment	O
groups	O
are	O
presented	O
in	O
Tables	O
4	O
and	O
5	O
.	O

The	O
SDR	O
models	O
achieving	O
optimal	O
prediction	O
performance	O
when	O
false	O
positive	O
predictions	O
are	O
given	O
the	O
same	O
importance	O
as	O
false	O
negative	O
predictions	O
are	O
marked	O
with	O
a	O
star	O
(*)	O
and	O
are	O
the	O
results	O
on	O
which	O
we	O
have	O
focused	O
.	O

Secondary	O
Results	O
(	O
Tadalafil	O
5mg	O
once	O
daily	O
).	O

Variable	O
Description	O

Sensitivity	O
%	O
(	O
95	O
%	O
CI	O
)	O

Specificity	O
%	O
(	O
95	O
%	O
CI	O
)	O

IPSS	O
QoL	O
improvement	O

Myocardial	B-DS
infarction	I-DS
(	O
Y	O
/	O
N	O
)	O

2	O
(	O
0	O
,	O
5	O
)	O

100	O
(	O
97	O
,	O
100	O
)	O

Smoking	O
(	O
Y	O
/	O
N	O
)	O

15	O
(	O
10	O
,	O
21	O
)	O

94	O
(	O
87	O
,	O
97	O
)	O

Number	O
of	O
anti	O
-	O
hypertensive	O
medications	O
*	O

48	O
(	O
41	O
,	O
56	O
)	O

66	O
(	O
56	O
,	O
75	O
)	O

Cardiovascular	B-DS
disorders	I-DS
cluster	O

57	O
(	O
49	O
,	O
64	O
)	O

58	O
(	O
48	O
,	O
68	O
)	O

Statins	O
(	O
Y	O
/	O
N	O
)	O

79	O
(	O
73	O
,	O
85	O
)	O

33	O
(	O
25	O
,	O
43	O
)	O

IPSS	O
QoL	O
(	O
baseline	O
)	O

98	O
(	O
95	O
,	O
99	O
)	O

11	O
(	O
6	O
,	O
19	O
)	O

Antidepressants	O
(	O
Y	O
/	O
N	O
)	O

99	O
(	O
96	O
,	O
100	O
)	O

6	O
(	O
3	O
,	O
13	O
)	O

IPSS	O
25	O
%	O
change	O

Qmax	O

10	O
(	O
6	O
,	O
16	O
)	O

94	O
(	O
89	O
,	O
98	O
)	O

IIEF	O
baseline	O
severity	O

19	O
(	O
14	O
,	O
26	O
)	O

89	O
(	O
82	O
,	O
94	O
)	O

Renal	B-DS
impairment	I-DS
II	I-DS

52	O
(	O
44	O
,	O
59	O
)	O

60	O
(	O
50	O
,	O
68	O
)	O

Hypertension	B-DS
treatment	O
phase	O
(	O
Y	O
/	O
N	O
)*	O

66	O
(	O
59	O
,	O
74	O
)	O

46	O
(	O
37	O
,	O
55	O
)	O

Hyperlipidemia	O
(	O
Y	O
/	O
N	O
)	O

81	O
(	O
74	O
,	O
87	O
)	O

29	O
(	O
22	O
,	O
38	O
)	O

IPSS	O
voiding	O
obstructive	O
subscore	O
(	O
baseline	O
)	O

95	O
(	O
91	O
,	O
98	O
)	O

13	O
(	O
7	O
,	O
20	O
)	O

Cluster	O
antidepressant	O
-	O
antipsychotic	O

99	O
(	O
96	O
,	O
100	O
)	O

5	O
(	O
2	O
,	O
10	O
)	O

Renal	B-DS
impairment	I-DS
I	I-DS

100	O
(	O
98	O
,	O
NaN	O
)	O

2	O
(	O
0	O
,	O
6	O
)	O

IPSS	O
Score	O
<	O
12	O

IPSS	O
total	O
score	O
(	O
baseline	O
)*	O

60	O
(	O
52	O
,	O
68	O
)	O

78	O
(	O
70	O
,	O
85	O
)	O

IPSS	O
baseline	O
group	O

80	O
(	O
73	O
,	O
86	O
)	O

58	O
(	O
50	O
,	O
67	O
)	O

Previous	O
overactive	B-DS
bladder	I-DS
therapy	O
(	O
Y	O
/	O
N	O
)	O

100	O
(	O
98	O
,	O
NaN	O
)	O

2	O
(	O
0	O
,	O
6	O
)	O

BII	O
Score	O
<	O
9	O

Ethnicity	O

7	O
(	O
4	O
,	O
10	O
)	O

100	O
(	O
79	O
,	O
100	O
)	O

IPSS	O
QoL	O
(	O
baseline	O
)	O

51	O
(	O
45	O
,	O
57	O
)	O

88	O
(	O
62	O
,	O
98	O
)	O

BII	O
total	O
score	O
(	O
baseline	O
)*	O

68	O
(	O
62	O
,	O
73	O
)	O

75	O
(	O
48	O
,	O
93	O
)	O

Antidepressants	O
(	O
Y	O
/	O
N	O
)	O

98	O
(	O
95	O
,	O
99	O
)	O

6	O
(	O
0	O
,	O
30	O
)	O

BII	O
improvement	O

Number	O
of	O
anti	O
-	O
hypertensive	O
medications	O
**	O

2	O
(	O
1	O
,	O
6	O
)	O

99	O
(	O
95	O
,	O
100	O
)	O

BII	O
total	O
score	O
(	O
baseline	O
)*	O

97	O
(	O
93	O
,	O
99	O
)	O

25	O
(	O
17	O
,	O
34	O
)	O

PGI	O
-	O
I	O

%	O
bioavailable	O
testosterone	O
*	O

62	O
(	O
24	O
,	O
91	O
)	O

84	O
(	O
78	O
,	O
89	O
)	O

Cluster	O
anti	O
-	O
hypertensive	O
drugs	O

88	O
(	O
47	O
,	O
100	O
)	O

44	O
(	O
37	O
,	O
52	O
)	O

Albumin	B-GP
(	O
baseline	O
)	O

100	O
(	O
63	O
,	O
NaN	O
)	O

17	O
(	O
12	O
,	O
23	O
)	O

*	O
Model	O
on	O
ROC	O
surface	O
with	O
best	O
performance	O
if	O
false	O
positive	O
and	O
false	O
negative	O
errors	O
are	O
equally	O
important	O
.	O

**	O
Alpha	O
-	O
Blockers	O
,	O
beta	O
-	O
blockers	O
,	O
calcium	B-GP
channels	I-GP
blockers	O
,	O
angiotensin	B-GP
converting	I-GP
enzyme	I-GP
inhibitors	O
,	O
angiotensin	B-GP
receptor	I-GP
blockers	O
and	O
diuretics	O
.	O

BII	O
,	O
BPH	B-DS
Impact	O
Index	O
;	O
CI	O
,	O
confidence	O
interval	O
;	O
IIEF	O
,	O
International	O
Index	O
of	O
Erectile	O
Function	O
;	O
IPSS	O
,	O
International	O
Prostate	O
Symptom	O
Score	O
;	O
N	O
,	O
no	O
;	O
PGI	O
,	O
Patient	O
Global	O
Impression	O
of	O
Improvement	O
;	O
Qmax	O
,	O
maximal	O
flow	O
rate	O
;	O
QoL	O
,	O
quality	O
of	O
life	O
;	O
ROC	O
,	O
Receiver	O
Operating	O
Curve	O
;	O
Y	O
,	O
yes	O
.	O

Secondary	O
Results	O
(	O
Placebo	O
).	O

Variable	O
Description	O

Sensitivity	O
%	O
(	O
95	O
%	O
CI	O
)	O

Specificity	O
%	O
(	O
95	O
%	O
CI	O
)	O

IPSS	O
QoL	O
improvement	O

Free	O
testosterone	O

7	O
(	O
4	O
,	O
13	O
)	O

97	O
(	O
93	O
,	O
99	O
)	O

ED	B-DS
duration	O

16	O
(	O
11	O
,	O
23	O
)	O

91	O
(	O
85	O
,	O
95	O
)	O

ED	B-DS
etiology	O
*	O

37	O
(	O
29	O
,	O
45	O
)	O

76	O
(	O
69	O
,	O
83	O
)	O

IPSS	O
QoL	O
(	O
baseline	O
)	O

89	O
(	O
83	O
,	O
93	O
)	O

22	O
(	O
16	O
,	O
30	O
)	O

Number	O
of	O
anti	O
-	O
hypertensive	O
medications	O
**	O

99	O
(	O
96	O
,	O
100	O
)	O

3	O
(	O
1	O
,	O
7	O
)	O

IPSS	O
25	O
%	O
Change	O

ED	B-DS
duration	O

4	O
(	O
1	O
,	O
9	O
)	O

100	O
(	O
98	O
,	O
100	O
)	O

Ethnicity	O

10	O
(	O
6	O
,	O
17	O
)	O

96	O
(	O
92	O
,	O
98	O
)	O

Cluster	O
anti	O
-	O
hypertensive	O
Drugs	O

52	O
(	O
43	O
,	O
61	O
)	O

63	O
(	O
55	O
,	O
70	O
)	O

PGI	O
-	O
S	O
baseline	O
*	O

69	O
(	O
60	O
,	O
77	O
)	O

48	O
(	O
41	O
,	O
56	O
)	O

IIEF	O
-	O
IS	O
(	O
baseline	O
)	O

85	O
(	O
77	O
,	O
91	O
)	O

29	O
(	O
22	O
,	O
36	O
)	O

Other	O
lipid	O
lowering	O
drugs	O
(	O
Y	O
/	O
N	O
)	O

99	O
(	O
96	O
,	O
100	O
)	O

6	O
(	O
3	O
,	O
11	O
)	O

IPSS	O
Score	O
<	O
12	O

Ethnicity	O

13	O
(	O
8	O
,	O
20	O
)	O

95	O
(	O
91	O
,	O
98	O
)	O

IPSS	O
storage	O
irritative	O
subscore	O
(	O
baseline	O
)	O

58	O
(	O
49	O
,	O
67	O
)	O

75	O
(	O
68	O
,	O
81	O
)	O

IPSS	O
total	O
score	O
(	O
baseline	O
)*	O

69	O
(	O
60	O
,	O
77	O
)	O

68	O
(	O
60	O
,	O
75	O
)	O

IPSS	O
baseline	O
group	O

81	O
(	O
73	O
,	O
88	O
)	O

51	O
(	O
43	O
,	O
58	O
)	O

Other	O
lipid	O
lowering	O
drugs	O
(	O
Y	O
/	O
N	O
)	O

100	O
(	O
97	O
,	O
NaN	O
)	O

4	O
(	O
2	O
,	O
8	O
)	O

BII	O
Score	O
<	O
9	O

Ethnicity	O

8	O
(	O
5	O
,	O
11	O
)	O

100	O
(	O
85	O
,	O
100	O
)	O

IPSS	O
baseline	O
group	O
*	O

72	O
(	O
66	O
,	O
77	O
)	O

91	O
(	O
71	O
,	O
99	O
)	O

BII	O
total	O
score	O
(	O
baseline	O
)	O

89	O
(	O
85	O
,	O
93	O
)	O

64	O
(	O
41	O
,	O
83	O
)	O

BII	O
Improvement	O

Alcohol	O
frequency	O

3	O
(	O
1	O
,	O
7	O
)	O

98	O
(	O
95	O
,	O
100	O
)	O

IPSS	O
baseline	O
group	O

45	O
(	O
37	O
,	O
53	O
)	O

73	O
(	O
64	O
,	O
80	O
)	O

BII	O
total	O
score	O
(	O
baseline	O
)*	O

87	O
(	O
81	O
,	O
92	O
)	O

41	O
(	O
32	O
,	O
50	O
)	O

IPSS	O
storage	O
irritative	O
subscore	O
(	O
baseline	O
)	O

96	O
(	O
92	O
,	O
99	O
)	O

16	O
(	O
10	O
,	O
23	O
)	O

PGI	O
-	O
I	O

Testosterone	O
(	O
baseline	O
)	O

18	O
(	O
2	O
,	O
52	O
)	O

92	O
(	O
87	O
,	O
96	O
)	O

SHBG	B-GP
(	O
baseline	O
)*	O

91	O
(	O
59	O
,	O
100	O
)	O

47	O
(	O
39	O
,	O
54	O
)	O

Renal	B-DS
impairment	I-DS
I	I-DS

100	O
(	O
72	O
,	O
NaN	O
)	O

32	O
(	O
25	O
,	O
39	O
)	O

*	O
Model	O
on	O
ROC	O
surface	O
with	O
best	O
performance	O
if	O
false	O
positive	O
and	O
false	O
negative	O
errors	O
are	O
equally	O
important	O
.	O

**	O
Alpha	O
-	O
Blockers	O
,	O
beta	O
-	O
blockers	O
,	O
calcium	B-GP
channels	I-GP
blockers	O
,	O
angiotensin	B-GP
converting	I-GP
enzyme	I-GP
inhibitors	O
,	O
angiotensin	B-GP
receptor	I-GP
blockers	O
and	O
diuretics	O
.	O

BII	O
,	O
BPH	B-DS
Impact	O
Index	O
;	O
CI	O
,	O
confidence	O
interval	O
;	O
ED	B-DS
,	O
erectile	B-DS
dysfunction	I-DS
;	O
IIEF	O
,	O
International	O
Index	O
of	O
Erectile	O
Function	O
;	O
IPSS	O
,	O
International	O
Prostate	O
Symptom	O
Score	O
;	O
N	O
,	O
no	O
;	O
PGI	O
-	O
I	O
,	O
Patient	O
Global	O
Impression	O
of	O
Improvement	O
;	O
PGISS	O
,	O
Patient	O
Global	O
Incontinence	B-DS
Severity	O
Score	O
;	O
QoL	O
,	O
quality	O
of	O
life	O
;	O
ROC	O
,	O
Receiver	O
Operating	O
Curve	O
;	O
SHBG	B-GP
,	O
sex	B-GP
hormone	I-GP
binding	I-GP
globulin	I-GP
;	O
Y	O
,	O
yes	O
.	O

A	O
reduction	O
of	O
≥	O
1	O
point	O
on	O
the	O
IPSS	O
QoL	O
question	O
was	O
the	O
first	O
secondary	O
objective	O
.	O

SDR	O
models	O
found	O
on	O
the	O
ROC	O
surfaces	O
included	O
number	O
of	O
anti	O
-	O
hypertensive	O
medications	O
for	O
the	O
tadalafil	O
5mg	O
once	O
daily	O
group	O
,	O
and	O
ED	B-DS
etiology	O
(	O
mixed	O
or	O
psychogenic	O
)	O
for	O
the	O
placebo	O
group	O
to	O
predict	O
improvements	O
.	O

A	O
reduction	O
in	O
the	O
IPSS	O
total	O
score	O
of	O
25	O
%	O
from	O
baseline	O
to	O
12	O
weeks	O
was	O
the	O
next	O
secondary	O
objective	O
,	O
and	O
SDR	O
models	O
on	O
the	O
ROC	O
surface	O
included	O
presence	O
of	O
hypertension	B-DS
during	O
treatment	O
for	O
the	O
tadalafil	O
group	O
and	O
PGI	O
-	O
S	O
(<	O
5	O
)	O
at	O
baseline	O
for	O
the	O
placebo	O
group	O
.	O

Achieving	O
an	O
IPSS	O
total	O
score	O
<	O
12	O
points	O
at	O
12	O
weeks	O
was	O
the	O
third	O
secondary	O
objective	O
.	O

An	O
IPSS	O
score	O
<	O
12	O
was	O
predicted	O
using	O
IPSS	O
total	O
score	O
for	O
the	O
tadalafil	O
5mg	O
once	O
daily	O
and	O
placebo	O
groups	O
.	O

Cut	O
-	O
off	O
for	O
response	O
was	O
selected	O
as	O
<	O
16	O
for	O
tadalafil	O
5mg	O
once	O
daily	O
and	O
placebo	O
by	O
SDR	O
models	O
on	O
the	O
ROC	O
surface	O
giving	O
equal	O
importance	O
to	O
false	O
positive	O
and	O
false	O
negative	O
predictions	O
.	O

A	O
reduction	O
to	O
<	O
9	O
points	O
on	O
the	O
BII	O
total	O
score	O
after	O
12	O
weeks	O
treatment	O
was	O
the	O
fourth	O
secondary	O
objective	O
.	O

IPSS	O
severity	O
(	O
mild	O
/	O
moderate	O
)	O
was	O
used	O
to	O
predict	O
BII	O
<	O
9	O
after	O
12	O
weeks	O
treatment	O
for	O
the	O
placebo	O
group	O
,	O
while	O
the	O
BII	O
total	O
score	O
(<	O
6	O
.	O
5	O
)	O
was	O
used	O
by	O
the	O
SDR	O
predicting	O
response	O
/	O
improvement	O
in	O
tadalafil	O
-	O
treated	O
patients	O
.	O

A	O
reduction	O
of	O
>	O
0	O
.	O
5	O
point	O
on	O
the	O
BII	O
scale	O
was	O
the	O
fifth	O
secondary	O
objective	O
.	O

BII	O
total	O
score	O
at	O
baseline	O
was	O
used	O
to	O
predict	O
any	O
improvements	O
in	O
BII	O
by	O
the	O
SDR	O
models	O
.	O

The	O
cut	O
-	O
offs	O
employed	O
were	O
≥	O
1	O
.	O
5	O
and	O
≥	O
2	O
.	O
5	O
for	O
response	O
in	O
the	O
tadalafil	O
5mg	O
once	O
daily	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

The	O
final	O
secondary	O
objective	O
was	O
any	O
improvement	O
on	O
the	O
PGI	O
scale	O
.	O

SDR	O
models	O
lying	O
on	O
the	O
ROC	O
surface	O
that	O
gave	O
equal	O
importance	O
to	O
false	O
positives	O
and	O
false	O
negatives	O
in	O
predicting	O
improvements	O
were	O
,	O
%	O
bioavailable	O
testosterone	O
(≥	O
35	O
%)	O
for	O
the	O
tadalafil	O
5mg	O
once	O
daily	O
group	O
and	O
sex	B-GP
hormone	I-GP
binding	I-GP
globulin	I-GP
(	O
SHBG	B-GP
)	O
(<	O
42nmol	O
/	O
l	O
)	O
for	O
the	O
placebo	O
group	O
,	O
respectively	O
.	O

Post	O
-	O
hoc	O
Sensitivity	O
Analysis	O

All	O
pre	O
-	O
specified	O
analyses	O
returned	O
only	O
SDR	O
models	O
.	O

LR	O
,	O
SVM	O
,	O
RF	O
and	O
DT	O
approaches	O
did	O
not	O
yield	O
models	O
because	O
missing	O
values	O
,	O
that	O
included	O
parameters	O
that	O
were	O
either	O
not	O
measured	O
or	O
intended	O
for	O
collection	O
,	O
resulted	O
in	O
an	O
insufficient	O
number	O
of	O
complete	O
patient	O
records	O
.	O

Testosterone	O
measurements	O
were	O
the	O
key	O
driver	O
,	O
responsible	O
for	O
79	O
%	O
of	O
incomplete	O
records	O
,	O
while	O
missing	O
PSA	B-GP
assessments	O
accounted	O
for	O
70	O
%	O
of	O
records	O
,	O
followed	O
by	O
frequency	O
of	O
alcohol	O
intake	O
and	O
SHBG	B-GP
assessments	O
(	O
both	O
missing	O
in	O
>	O
30	O
%	O
of	O
cases	O
).	O

Finally	O
,	O
PGI	O
assessment	O
(	O
PGI	O
-	O
I	O
was	O
assessed	O
in	O
only	O
3	O
of	O
the	O
4	O
studies	O
),	O
previous	O
overactive	B-DS
bladder	I-DS
therapy	O
,	O
ED	B-DS
characteristics	O
and	O
assessment	O
of	O
Qmax	O
were	O
missing	O
for	O
20	O
%	O
to	O
30	O
%	O
of	O
patients	O
.	O

Table	O
6	O
details	O
sensitivities	O
and	O
specificities	O
on	O
held	O
-	O
out	O
test	O
data	O
from	O
non	O
-	O
SDR	O
models	O
lying	O
on	O
the	O
ROC	O
surface	O
when	O
testosterone	O
,	O
alcohol	O
intake	O
,	O
Qmax	O
,	O
SHBG	B-GP
,	O
albumin	B-GP
,	O
PGI	O
-	O
S	O
and	O
PSA	B-GP
were	O
excluded	O
.	O

For	O
13	O
of	O
these	O
models	O
,	O
pre	O
-	O
selection	O
via	O
a	O
t	O
-	O
test	O
filter	O
improved	O
prediction	O
performance	O
(	O
S7	O
Technical	O
Appendix	O
).	O

In	O
these	O
cases	O
the	O
pre	O
-	O
selected	O
variables	O
are	O
given	O
in	O
the	O
last	O
column	O
of	O
the	O
table	O
.	O

Only	O
4	O
of	O
the	O
models	O
were	O
RF	O
;	O
not	O
a	O
single	O
SVM	O
was	O
observed	O
.	O

Of	O
the	O
better	O
performing	O
models	O
,	O
sensitivity	O
and	O
specificity	O
were	O
best	O
with	O
respect	O
to	O
BII	O
total	O
score	O
of	O
<	O
9	O
.	O

DTs	O
for	O
the	O
tadalafil	O
5mg	O
once	O
daily	O
group	O
achieved	O
a	O
sensitivity	O
of	O
77	O
%	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
72	O
,	O
0	O
.	O
82	O
)	O
and	O
specificity	O
of	O
62	O
%	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
35	O
,	O
0	O
.	O
85	O
).	O

Exploratory	O
Results	O
.	O

Groups	O

Model	O

Sensitivity	O
%	O
(	O
95	O
%	O
CI	O
)	O

Specificity	O
%	O
(	O
95	O
%	O
CI	O
)	O

Variables	O
included	O
,	O
if	O
based	O
on	O
feature	O
selection	O

Severity	O
MCID	O

Placebo	O

DT	O

58	O
(	O
50	O
,	O
66	O
)	O

56	O
(	O
47	O
,	O
65	O
)	O

Overall	O
MCID	O

Tadalafil	O

DT	O

67	O
(	O
60	O
,	O
74	O
)	O

51	O
(	O
40	O
,	O
61	O
)	O

IPSS	O
total	O
and	O
storage	O
score	O

Placebo	O

DT	O

92	O
(	O
87	O
,	O
96	O
)	O

25	O
(	O
18	O
,	O
33	O
)	O

IPSS	O
total	O
and	O
voiding	O
score	O

QoL	O
Improvement	O

Tadalafil	O

DT	O

88	O
(	O
83	O
,	O
92	O
)	O

31	O
(	O
23	O
,	O
41	O
)	O

IPSS	O
QoL	O
score	O

Tadalafil	O

DT	O

58	O
(	O
51	O
,	O
65	O
)	O

63	O
(	O
53	O
,	O
72	O
)	O

Placebo	O

RF	O

61	O
(	O
53	O
,	O
69	O
)	O

55	O
(	O
46	O
,	O
63	O
)	O

IPSS	O
QoL	O
score	O

Placebo	O

DT	O

89	O
(	O
83	O
,	O
93	O
)	O

22	O
(	O
16	O
,	O
30	O
)	O

IPSS	O
QoL	O
score	O

IPSS	O
25	O
%	O

BII	O
<	O
9	O

Tadalafil	O

RF	O

99	O
(	O
97	O
,	O
100	O
)	O

6	O
(	O
0	O
,	O
30	O
)	O

BII	O
total	O
score	O
,	O
IPSS	O
total	O
,	O
voiding	O
and	O
storage	O
,	O
IPSS	O
QoL	O
score	O

Tadalafil	O

DT	O

77	O
(	O
72	O
,	O
82	O
)	O

62	O
(	O
35	O
,	O
85	O
)	O

BII	O
total	O
score	O
,	O
IPSS	O
total	O
,	O
voiding	O
and	O
storage	O
,	O
IPSS	O
QoL	O
score	O

Placebo	O

RF	O

98	O
(	O
96	O
,	O
99	O
)	O

23	O
(	O
8	O
,	O
45	O
)	O

Number	O
of	O
anti	O
-	O
hypertensive	O
treatments	O
,	O
Study	O
treatment	O
compliance	O
,	O
BII	O
total	O
score	O
baseline	O
,	O
IPSS	O
storage	O
,	O
voiding	O
and	O
total	O
score	O
,	O
Cardiovascular	B-DS
disorders	I-DS
cluster	O
,	O
Cluster	O
cardiovascular	B-DS
disorders	I-DS
(	O
CLUSTCARDVDIS	O
),	O
Cluster	O
anti	O
-	O
diabetic	O
drugs	O

BII	O
Improvement	O

Tadalafil	O

RF	O

65	O
(	O
57	O
,	O
72	O
)	O

60	O
(	O
50	O
,	O
69	O
)	O

BII	O
total	O
score	O

Placebo	O

DT	O

72	O
(	O
64	O
,	O
79	O
)	O

58	O
(	O
49	O
,	O
67	O
)	O

BII	O
and	O
IPSS	O
total	O
score	O
,	O
IPSS	O
voiding	O
score	O

PGI	O
Improvement	O

Placebo	O

DT	O

64	O
(	O
31	O
,	O
89	O
)	O

69	O
(	O
61	O
,	O
75	O
)	O

Models	O
were	O
generated	O
on	O
dataset	O
excluding	O
testosterone	O
,	O
alcohol	O
frequency	O
,	O
Qmax	O
,	O
SHBG	B-GP
,	O
Albumin	B-GP
,	O
PGI	O
,	O
and	O
PSA	B-GP

BII	O
,	O
BPH	B-DS
Impact	O
Index	O
;	O
CI	O
,	O
confidence	O
interval	O
;	O
DT	O
,	O
Decision	O
Tree	O
;	O
IPSS	O
,	O
International	O
Prostate	O
Symptom	O
Score	O
;	O
MCID	O
,	O
Minimally	O
Clinically	O
Important	O
Differences	O
;	O
PGI	O
-	O
I	O
,	O
Patient	O
Global	O
Impression	O
of	O
Improvement	O
;	O
PSA	B-GP
,	O
prostate	B-GP
specific	I-GP
antigen	I-GP
;	O
Qmax	O
,	O
maximal	O
flow	O
rate	O
;	O
QoL	O
,	O
quality	O
of	O
life	O
;	O
RF	O
,	O
Random	O
Forest	O
;	O
SHBG	B-GP
,	O
sex	B-GP
hormone	I-GP
binding	I-GP
globulin	I-GP
.	O

Discussion	O

Identifying	O
predictors	O
of	O
response	O
to	O
drug	O
therapy	O
can	O
be	O
beneficial	O
,	O
especially	O
where	O
significant	O
improvements	O
in	O
patient	O
health	O
-	O
related	O
QoL	O
are	O
sought	O
,	O
such	O
as	O
in	O
LUTS	O
-	O
BPH	B-DS
where	O
symptom	O
relief	O
is	O
the	O
primary	O
goal	O
of	O
treatment	O
for	O
the	O
majority	O
of	O
men	O
.	O

It	O
also	O
has	O
benefits	O
in	O
an	O
era	O
where	O
patients	O
are	O
encouraged	O
to	O
take	O
an	O
active	O
role	O
in	O
treatment	O
decisions	O
alongside	O
their	O
physician	O
.	O

The	O
objective	O
of	O
this	O
clinical	O
data	O
mining	O
study	O
was	O
to	O
identify	O
prediction	O
models	O
and	O
associated	O
patient	O
baseline	O
characteristics	O
that	O
could	O
be	O
used	O
in	O
clinical	O
practice	O
to	O
predict	O
treatment	O
response	O
to	O
tadalafil	O
5mg	O
once	O
daily	O
among	O
patients	O
with	O
a	O
diagnosis	O
of	O
LUTS	O
-	O
BPH	B-DS
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
clinical	O
data	O
mining	O
analysis	O
to	O
use	O
mathematical	O
modelling	O
in	O
studies	O
of	O
patients	O
with	O
LUTS	O
-	O
BPH	B-DS
.	O

To	O
meet	O
this	O
objective	O
,	O
we	O
adopted	O
a	O
rigorous	O
data	O
mining	O
approach	O
involving	O
commonly	O
used	O
models	O
and	O
evaluated	O
their	O
discriminative	O
ability	O
on	O
held	O
-	O
out	O
data	O
using	O
eight	O
different	O
measures	O
of	O
treatment	O
response	O
and	O
107	O
possible	O
predictors	O
.	O

These	O
were	O
chosen	O
from	O
a	O
large	O
patient	O
population	O
enrolled	O
in	O
a	O
series	O
of	O
almost	O
identical	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
studies	O
of	O
the	O
same	O
duration	O
of	O
randomized	O
treatment	O
and	O
with	O
similar	O
inclusion	O
/	O
exclusion	O
criteria	O
.	O

Results	O
were	O
backed	O
up	O
by	O
repeated	O
evaluations	O
and	O
comparison	O
to	O
non	O
-	O
informative	O
data	O
to	O
control	O
for	O
bias	O
.	O

As	O
our	O
results	O
have	O
demonstrated	O
,	O
we	O
did	O
not	O
to	O
obtain	O
any	O
sensitivities	O
or	O
specificities	O
above	O
an	O
80	O
%	O
threshold	O
for	O
the	O
specified	O
baseline	O
characteristics	O
.	O

In	O
other	O
words	O
,	O
at	O
this	O
threshold	O
there	O
would	O
be	O
a	O
20	O
%	O
risk	O
of	O
an	O
incorrect	O
prediction	O
,	O
which	O
we	O
would	O
argue	O
is	O
an	O
acceptable	O
basis	O
on	O
which	O
to	O
predict	O
treatment	O
response	O
in	O
a	O
non	O
-	O
malignant	O
condition	O
in	O
clinical	O
practice	O
.	O

Thus	O
,	O
using	O
our	O
data	O
from	O
four	O
clinical	O
trials	O
and	O
modelling	O
methods	O
,	O
no	O
single	O
predictive	O
rule	O
emerged	O
from	O
which	O
a	O
treatment	O
algorithm	O
could	O
be	O
developed	O
to	O
clinically	O
guide	O
the	O
use	O
of	O
tadalafil	O
5mg	O
once	O
daily	O
in	O
patients	O
with	O
LUTS	O
-	O
BPH	B-DS
.	O

Similarly	O
,	O
we	O
found	O
no	O
characteristics	O
that	O
determined	O
response	O
to	O
LUTS	O
-	O
BPH	B-DS
treatment	O
when	O
placebo	O
is	O
used	O
.	O

These	O
findings	O
applied	O
to	O
both	O
primary	O
and	O
secondary	O
objectives	O
.	O

Across	O
the	O
107	O
baseline	O
characteristics	O
,	O
there	O
was	O
evidence	O
that	O
with	O
respect	O
to	O
‘	O
severity	O
MCID	O
’,	O
LUTS	O
severity	O
at	O
baseline	O
as	O
measured	O
by	O
IPSS	O
score	O
(	O
mild	O
-	O
moderate	O
≤	O
20	O
vs	O
.	O
severe	O
>	O
20	O
)	O
had	O
sensitivity	O
and	O
specificity	O
levels	O
that	O
approached	O
70	O
%	O
and	O
50	O
%,	O
respectively	O
.	O

While	O
this	O
level	O
of	O
prediction	O
is	O
marginally	O
better	O
than	O
random	O
guessing	O
,	O
it	O
is	O
still	O
too	O
low	O
for	O
clinical	O
use	O
.	O

However	O
,	O
IPSS	O
continues	O
to	O
underpin	O
assessments	O
with	O
respect	O
to	O
baseline	O
symptom	O
severity	O
and	O
monitoring	O
symptom	O
progression	O
in	O
cases	O
of	O
“	O
watchful	O
waiting	O
”	O
[	O
34	O
].	O

This	O
may	O
be	O
due	O
to	O
the	O
fact	O
that	O
during	O
its	O
validation	O
,	O
care	O
was	O
taken	O
to	O
generate	O
a	O
predictive	O
questionnaire	O
[	O
10	O
;	O
21	O
].	O

Several	O
analyses	O
of	O
pooled	O
data	O
from	O
the	O
four	O
clinical	O
trials	O
of	O
tadalafil	O
versus	O
placebo	O
that	O
were	O
used	O
in	O
this	O
clinical	O
data	O
mining	O
study	O
have	O
shown	O
that	O
tadalafil	O
significantly	O
improves	O
symptoms	O
of	O
LUTS	O
-	O
BPH	B-DS
,	O
including	O
small	O
but	O
significant	O
improvements	O
in	O
Qmax	O
[	O
35	O
]	O
with	O
concomitant	O
improvements	O
in	O
QoL	O
[	O
11	O
;	O
36	O
].	O

Subsequent	O
analyses	O
revealed	O
improvement	O
in	O
both	O
IPSS	O
storage	O
and	O
voiding	O
subscores	O
[	O
12	O
],	O
and	O
that	O
improvements	O
in	O
LUTS	O
occurred	O
irrespective	O
of	O
the	O
presence	O
of	O
co	O
-	O
existing	O
ED	B-DS
[	O
37	O
].	O

Thus	O
,	O
tadalafil	O
has	O
therapeutic	O
benefit	O
beyond	O
its	O
effects	O
on	O
ED	B-DS
in	O
men	O
with	O
comorbid	O
LUTS	O
-	O
BPH	B-DS
.	O

These	O
findings	O
have	O
been	O
confirmed	O
in	O
a	O
prospective	O
,	O
naturalistic	O
observational	O
study	O
(	O
TadaLutsEd	O
),	O
which	O
closely	O
mirrors	O
routine	O
clinical	O
practice	O
.	O

In	O
this	O
non	O
-	O
selective	O
study	O
,	O
86	O
%	O
of	O
men	O
aged	O
50	O
years	O
and	O
older	O
with	O
LUTS	O
-	O
BPH	B-DS
saw	O
an	O
improvement	O
in	O
urinary	O
symptoms	O
following	O
6	O
weeks	O
treatment	O
with	O
tadalafil	O
5mg	O
once	O
daily	O
[	O
38	O
].	O

A	O
subgroup	O
analysis	O
of	O
the	O
effects	O
of	O
tadalafil	O
in	O
various	O
patient	O
subgroups	O
concluded	O
that	O
tadalafil	O
improves	O
LUTS	O
-	O
BPH	B-DS
symptoms	O
,	O
as	O
measured	O
by	O
the	O
IPSS	O
,	O
across	O
all	O
clinical	O
subgroups	O
that	O
included	O
LUTS	O
severity	O
(	O
IPSS	O
≤	O
20	O
/>	O
20	O
)	O
and	O
previous	O
use	O
of	O
α	O
-	O
blocking	O
agents	O
[	O
13	O
].	O

However	O
,	O
while	O
this	O
analysis	O
looked	O
at	O
the	O
various	O
subgroups	O
from	O
a	O
population	O
perspective	O
and	O
,	O
as	O
such	O
,	O
evaluates	O
improvement	O
on	O
average	O
,	O
our	O
work	O
crucially	O
looks	O
at	O
it	O
from	O
the	O
perspective	O
of	O
the	O
physician	O
and	O
the	O
individual	O
patient	O
(	O
i	O
.	O
e	O
.	O
predicting	O
the	O
improvement	O
on	O
an	O
individual	O
basis	O
).	O

Both	O
analyses	O
are	O
consistent	O
in	O
that	O
efficacy	O
occurred	O
across	O
all	O
subgroups	O
in	O
the	O
pooled	O
analysis	O
of	O
data	O
from	O
the	O
four	O
clinical	O
trials	O
,	O
while	O
no	O
reliable	O
predictor	O
of	O
response	O
was	O
found	O
in	O
our	O
analysis	O
of	O
the	O
same	O
trials	O
on	O
an	O
individual	O
patient	O
basis	O
.	O

Given	O
that	O
tadalafil	O
provides	O
early	O
symptomatic	O
relief	O
[	O
6	O
]	O
across	O
a	O
wide	O
range	O
of	O
men	O
with	O
LUTS	O
-	O
BPH	B-DS
,	O
including	O
those	O
with	O
ED	B-DS
and	O
other	O
significant	O
comorbidities	O
,	O
it	O
is	O
perhaps	O
not	O
surprising	O
that	O
we	O
were	O
unable	O
to	O
identify	O
individual	O
predictors	O
of	O
response	O
to	O
placebo	O
or	O
tadalafil	O
5mg	O
once	O
daily	O
despite	O
rigorous	O
data	O
mining	O
.	O

Many	O
examples	O
exist	O
in	O
the	O
literature	O
of	O
predictors	O
of	O
response	O
(	O
or	O
failure	O
to	O
respond	O
)	O
to	O
drug	O
therapy	O
that	O
include	O
the	O
use	O
of	O
drugs	O
for	O
LUTS	O
-	O
BPH	B-DS
.	O

For	O
example	O
,	O
large	O
prostate	O
volume	O
and	O
more	O
severe	O
symptoms	O
at	O
baseline	O
have	O
been	O
identified	O
as	O
predictive	O
factors	O
for	O
failure	O
to	O
respond	O
to	O
first	O
-	O
line	O
medical	O
therapy	O
for	O
LUTS	O
-	O
BPH	B-DS
[	O
39	O
].	O

Severity	O
of	O
symptoms	O
is	O
a	O
strong	O
influence	O
on	O
the	O
extent	O
to	O
which	O
patients	O
judge	O
treatment	O
to	O
give	O
clinically	O
meaningful	O
improvement	O
[	O
19	O
]–	O
greater	O
severity	O
requires	O
a	O
proportionately	O
greater	O
improvement	O
in	O
symptom	O
relief	O
for	O
patients	O
to	O
perceive	O
the	O
same	O
degree	O
of	O
improvement	O
as	O
those	O
with	O
less	O
severe	O
disease	O
[	O
16	O
].	O

A	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
of	O
the	O
use	O
of	O
PDE	B-GP
-	I-GP
5	I-GP
inhibitors	O
in	O
LUTS	O
-	O
BPH	B-DS
suggested	O
that	O
younger	O
men	O
with	O
lower	O
BMI	O
and	O
severe	O
urinary	O
symptoms	O
were	O
the	O
best	O
candidates	O
for	O
PDE	B-GP
-	I-GP
5	I-GP
inhibitor	O
therapy	O
[	O
40	O
],	O
a	O
finding	O
we	O
were	O
unable	O
to	O
demonstrate	O
and	O
confirm	O
in	O
our	O
analysis	O
when	O
examining	O
patients	O
treated	O
with	O
tadalafil	O
or	O
using	O
placebo	O
.	O

We	O
did	O
,	O
however	O
,	O
identify	O
some	O
potential	O
candidates	O
for	O
predicting	O
treatment	O
response	O
.	O

In	O
addition	O
to	O
IPSS	O
-	O
related	O
characteristics	O
,	O
we	O
found	O
that	O
bioavailable	O
testosterone	O
,	O
ED	B-DS
etiology	O
,	O
cluster	O
of	O
lipid	O
-	O
lowering	O
medications	O
,	O
antidepressants	O
and	O
previous	O
use	O
of	O
5	B-GP
-	I-GP
α	I-GP
-	I-GP
reductase	I-GP
inhibitors	O
may	O
have	O
potential	O
as	O
predictors	O
for	O
treatment	O
response	O
,	O
especially	O
in	O
relation	O
to	O
‘	O
severity	O
MCID	O
’	O
response	O
.	O

Although	O
substantial	O
further	O
work	O
is	O
needed	O
to	O
test	O
these	O
observations	O
,	O
there	O
is	O
some	O
independent	O
evidence	O
to	O
suggest	O
that	O
some	O
,	O
if	O
not	O
all	O
,	O
may	O
be	O
viable	O
candidates	O
.	O

A	O
recent	O
study	O
on	O
the	O
effects	O
of	O
tadalafil	O
5mg	O
in	O
men	O
with	O
hypogonadism	B-DS
and	O
LUTS	O
-	O
BPH	B-DS
showed	O
that	O
while	O
tadalafil	O
was	O
effective	O
in	O
both	O
men	O
with	O
and	O
without	O
hypogonadism	B-DS
,	O
IPSS	O
storage	O
subscore	O
and	O
IPSS	O
-	O
QoL	O
was	O
appreciably	O
greater	O
in	O
men	O
without	O
hypogonadism	B-DS
than	O
those	O
with	O
low	O
testosterone	O
levels	O
[	O
41	O
].	O

There	O
is	O
also	O
evidence	O
to	O
suggest	O
that	O
depression	B-DS
,	O
anxiety	B-DS
and	O
somatization	B-DS
may	O
influence	O
the	O
clinical	O
manifestation	O
of	O
LUTS	O
-	O
BPH	B-DS
and	O
that	O
anxious	O
patients	O
respond	O
less	O
well	O
to	O
treatment	O
[	O
42	O
].	O

Conceivably	O
,	O
treatment	O
with	O
antidepressants	O
could	O
play	O
in	O
role	O
in	O
not	O
only	O
alleviating	O
symptoms	O
of	O
depression	B-DS
and	O
anxiety	B-DS
but	O
also	O
increasing	O
the	O
likelihood	O
of	O
response	O
to	O
specific	O
LUTS	O
-	O
BPH	B-DS
therapy	O
,	O
something	O
for	O
which	O
there	O
is	O
now	O
published	O
evidence	O
[	O
43	O
].	O

In	O
this	O
study	O
we	O
chose	O
to	O
use	O
established	O
models	O
for	O
prediction	O
,	O
such	O
as	O
LRs	O
,	O
DTs	O
,	O
SVMs	O
and	O
RFs	O
,	O
rather	O
than	O
newer	O
and	O
more	O
complex	O
models	O
.	O

Surprisingly	O
,	O
none	O
of	O
them	O
showed	O
robustness	O
with	O
regards	O
to	O
handling	O
missing	O
data	O
.	O

This	O
was	O
unexpected	O
,	O
especially	O
for	O
DTs	O
and	O
RFs	O
.	O

Current	O
data	O
mining	O
research	O
is	O
focused	O
on	O
developing	O
models	O
that	O
achieve	O
ever	O
better	O
prediction	O
methods	O
(	O
on	O
complete	O
datasets	O
),	O
while	O
simultaneously	O
ignoring	O
the	O
problem	O
of	O
missing	O
information	O
that	O
could	O
be	O
informative	O
but	O
could	O
also	O
completely	O
compromise	O
the	O
method	O
.	O

In	O
our	O
modelling	O
study	O
,	O
even	O
DTs	O
that	O
have	O
an	O
integrated	O
mechanism	O
for	O
dealing	O
with	O
missing	O
data	O
via	O
surrogate	O
splits	O
,	O
often	O
failed	O
to	O
achieve	O
better	O
performance	O
over	O
models	O
that	O
made	O
only	O
a	O
single	O
decision	O
.	O

Only	O
nine	O
DTs	O
were	O
found	O
on	O
the	O
ROC	O
surface	O
and	O
of	O
these	O
,	O
six	O
required	O
pre	O
-	O
selection	O
of	O
variables	O
via	O
a	O
t	O
-	O
test	O
filter	O
.	O

This	O
clearly	O
highlights	O
the	O
importance	O
of	O
this	O
issue	O
in	O
clinical	O
data	O
mining	O
research	O
.	O

Despite	O
its	O
strengths	O
,	O
which	O
include	O
a	O
pre	O
-	O
specified	O
program	O
of	O
statistical	O
analyses	O
,	O
this	O
study	O
has	O
several	O
limitations	O
.	O

Firstly	O
,	O
there	O
was	O
no	O
subsequent	O
independent	O
study	O
to	O
validate	O
our	O
results	O
.	O

It	O
is	O
also	O
possible	O
that	O
we	O
may	O
not	O
have	O
collected	O
the	O
“	O
true	O
factor	O
”	O
for	O
predicting	O
response	O
,	O
even	O
though	O
we	O
examined	O
107	O
baseline	O
characteristics	O
.	O

Better	O
methods	O
could	O
have	O
been	O
employed	O
to	O
fine	O
tune	O
model	O
parameters	O
,	O
especially	O
for	O
the	O
SVM	O
.	O

For	O
example	O
,	O
a	O
triple	O
split	O
set	O
evaluation	O
,	O
consisting	O
of	O
a	O
training	O
split	O
for	O
model	O
generation	O
,	O
a	O
validation	O
split	O
for	O
model	O
selection	O
,	O
and	O
test	O
split	O
for	O
hold	O
-	O
out	O
evaluation	O
could	O
have	O
been	O
used	O
to	O
fine	O
tune	O
the	O
selection	O
of	O
better	O
generalising	O
models	O
.	O

Evaluation	O
of	O
the	O
training	O
-	O
test	O
set	O
bias	O
did	O
not	O
,	O
however	O
,	O
indicate	O
a	O
need	O
for	O
such	O
additional	O
complexity	O
.	O

An	O
alternative	O
pre	O
-	O
filtering	O
step	O
could	O
have	O
been	O
used	O
,	O
adding	O
clustering	O
information	O
as	O
supportive	O
predictor	O
information	O
,	O
adding	O
de	O
-	O
noising	O
(	O
whitening	O
)	O
data	O
pre	O
-	O
processing	O
steps	O
,	O
or	O
using	O
statistical	O
bootstrapping	O
.	O

With	O
respect	O
to	O
SVM	O
,	O
we	O
employed	O
the	O
radial	O
basis	O
kernel	O
but	O
we	O
could	O
have	O
used	O
further	O
kernels	O
,	O
such	O
as	O
random	O
walk	O
kernels	O
,	O
optimal	O
matching	O
kernels	O
,	O
or	O
other	O
kernel	O
types	O
or	O
kernel	O
machines	O
for	O
training	O
this	O
algorithm	O
on	O
our	O
data	O
.	O

There	O
were	O
also	O
limitations	O
inherent	O
in	O
the	O
trial	O
inclusion	O
and	O
exclusion	O
criteria	O
;	O
for	O
example	O
,	O
patients	O
with	O
post	O
-	O
void	O
residual	O
urine	O
volume	O
>	O
300ml	O
were	O
excluded	O
and	O
prostate	O
volume	O
was	O
not	O
directly	O
assessed	O
,	O
although	O
PSA	B-GP
can	O
be	O
used	O
as	O
a	O
surrogate	O
for	O
prostate	O
size	O
.	O

In	O
conclusion	O
,	O
none	O
of	O
the	O
approaches	O
presented	O
here	O
led	O
to	O
a	O
prediction	O
model	O
with	O
sufficient	O
accuracy	O
for	O
the	O
development	O
of	O
a	O
tailoring	O
algorithm	O
for	O
tadalafil	O
5mg	O
once	O
daily	O
or	O
placebo	O
in	O
LUTS	O
-	O
BPH	B-DS
.	O

Thus	O
,	O
the	O
ideal	O
patient	O
profile	O
for	O
which	O
tadalafil	O
should	O
be	O
prescribed	O
with	O
respect	O
to	O
baseline	O
demographics	O
,	O
medical	O
history	O
,	O
IPSS	O
,	O
International	O
Index	O
of	O
Erectile	O
Function	O
(	O
IIEF	O
)	O
score	O
and	O
Qmax	O
remains	O
as	O
yet	O
unknown	O
.	O

Although	O
the	O
response	O
to	O
treatment	O
in	O
an	O
individual	O
patient	O
cannot	O
be	O
reliably	O
predicted	O
from	O
the	O
characteristics	O
and	O
methods	O
we	O
have	O
evaluated	O
so	O
far	O
,	O
this	O
does	O
not	O
mean	O
that	O
patients	O
with	O
LUTS	O
-	O
BPH	B-DS
are	O
not	O
likely	O
to	O
respond	O
on	O
average	O
to	O
treatment	O
with	O
placebo	O
or	O
tadalafil	O
5mg	O
once	O
daily	O
.	O

Among	O
the	O
approximately	O
two	O
-	O
thirds	O
of	O
men	O
with	O
LUTS	O
-	O
BPH	B-DS
who	O
achieved	O
CMI	O
following	O
treatment	O
with	O
tadalafil	O
5mg	O
,	O
over	O
half	O
achieved	O
CMI	O
after	O
one	O
week	O
of	O
therapy	O
and	O
over	O
70	O
%	O
within	O
4	O
weeks	O
[	O
44	O
].	O

Although	O
this	O
study	O
did	O
not	O
identify	O
any	O
pre	O
-	O
existing	O
patient	O
characteristics	O
that	O
might	O
predict	O
a	O
treatment	O
-	O
response	O
,	O
tadalafil	O
5mg	O
once	O
daily	O
has	O
been	O
shown	O
to	O
effectively	O
impact	O
LUTS	O
-	O
BPH	B-DS
across	O
a	O
range	O
of	O
patient	O
subgroups	O
.	O

Therefore	O
,	O
the	O
decision	O
to	O
treat	O
an	O
individual	O
case	O
of	O
LUTS	O
-	O
BPH	B-DS
with	O
tadalafil	O
5mg	O
once	O
daily	O
continues	O
to	O
rest	O
on	O
medical	O
assessment	O
of	O
the	O
patient	O
,	O
consideration	O
of	O
contra	O
-	O
indications	O
,	O
presence	O
of	O
co	O
-	O
existing	O
conditions	O
,	O
with	O
the	O
patient	O
’	O
s	O
expectations	O
and	O
preferences	O
leading	O
to	O
mutual	O
patient	O
-	O
physician	O
agreement	O
.	O

This	O
approach	O
is	O
entirely	O
compatible	O
with	O
the	O
current	O
concept	O
of	O
shared	O
decision	O
making	O
,	O
in	O
which	O
the	O
patient	O
’	O
s	O
voice	O
should	O
also	O
be	O
heard	O
as	O
an	O
integral	O
part	O
of	O
the	O
treatment	O
decision	O
[	O
45	O
],	O
especially	O
for	O
a	O
condition	O
in	O
which	O
part	O
of	O
the	O
symptomatic	O
improvement	O
is	O
a	O
strong	O
placebo	O
response	O
[	O
16	O
].	O

Supporting	O
Information	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

